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“Imagination is more important than knowledge. For knowledge is limited 
to all we now know and understand, while imagination embraces the 
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Introduction and Aims: Worldwide and across all age groups, asthma affects the lives of several 
hundred million people. In spite of the advances over the last decades, asthma and its multimorbidity 
continue to impart a significant onus on individuals with the disease, their families and society and also on 
health economies. A high number of unmet needs remain to be resolved, related to gaps in current 
scientific knowledge covering many aspects of asthma, from epidemiology and pathophysiology to patient 
care. The main objective of this dissertation was to contribute to address some of these existing unmet 
needs in asthma and its link with rhinitis. In particular, the original work aimed to (1) estimate nationwide 
asthma prevalence and analyze its association with rhinitis in particularly vulnerable and internationally 
data-lacking population groups – the children and the elderly; (2) unveil features for an early recognition 
of asthma, identifying multidimensional “hypothesis-free” early childhood wheezing clinical phenotypes 
related to asthma persistence in adolescence; (3) analyze the association between nasal and lower 
airway function, together with the subjective evaluation of allergic rhinitis and asthma concurrent control in 
children; (4) explore innovative strategies to uncover “unbiased” differentiating metabolic features of 
childhood allergic rhinitis and asthma multimorbidity in non-invasively collected samples. 
Methods: This dissertation was based on three types of studies: 
1. Cross-sectional, population-based, nationwide surveys of citizens living in Portugal, applied by 
interview using standardized procedures, to collect epidemiological data related to asthma and 
rhinitis and to analyze the association between these two conditions. For the pediatric study, data 
from all individuals aged below 18 years who participated in the INAsma study (population-based, 
all-age, nationwide telephone interview study to estimate asthma prevalence in Portugal) was 
analyzed. The elderly-targeted study was originally designed to estimate rhinitis prevalence in 
individuals aged 65 years or above living in mainland Portugal and the data was collected by 
direct face-to-face interview; 
2. Prospective cohort study of children aged below 7 years with recurrent wheezing, systematically 
evaluated at specific time-points, up to 13 years of follow-up. Multivariable logistic regression 
models for persistent asthma in adolescence were developed based on questionnaires and skin 
prick tests data. Clinical phenotypes were identified by cluster analysis of variables selected with 
the logistic regression analysis, and compared for predicting asthma prevalence, use of control 
treatments and lung function in childhood and adolescence; 
3. Cross-sectional, case-control study of school-aged children with allergic rhinitis and asthma 
multimorbidity and healthy children (matched for age and gender), evaluated with respect to: 
a. Respiratory functional laboratorial assessments, i.e., sequential assessments of peak 
nasal inspiratory flow (PNIF) before and after nasal decongestion and spirometry with 
bronchodilation test. The Control of Allergic Rhinitis and Asthma Test for children 
(CARATkids) was used for these diseases concurrent subjective control evaluation. 
Associations between objective and subjective scores were investigated by multiple 
linear regression models. 
b. Analytical laboratorial study using untargeted metabolomics analysis by nuclear magnetic 
resonance (NMR) spectroscopy of urine and saliva samples collected from each child. 
Spectroscopic and clinical data were subjected to statistical analysis including 
multivariable and univariable approaches. Additionally, exhaled breath condensate (EBC) 
samples were collected from volunteers, together with room air samples, which were 





Results: The estimated prevalence of current asthma in children was 8.4% (95% confidence interval (CI) 
6.6%-10.7%). The prevalence of rhinitis and of physician-diagnosed asthma in the elderly were estimated 
to be 29.8% (95%CI 28.4%-31.3%) and 10.9% (95%CI 9.9%-11.9%), respectively. A strong association 
between asthma and rhinitis at the population-level was found both in children (odds-ratio (OR) 5.2, 
95%CI 3.1-8.9) and in the elderly (OR varying from 8.3, 95%CI 6.1-11.4 in mild intermittent rhinitis to 
39.9, 95%CI 27.5-58.0 in moderate-severe persistent rhinitis). 
In the cohort study, atopy and rhinitis at preschool-age were independent risk factors for asthma 
persistence in adolescence (OR 11.8, 95%CI 4.0-34.6, and OR 10.4, 95%CI 3.7-29.1, respectively). 
Three distinct early childhood wheezing phenotypes were identified, which were predictive of asthma 
persistence, use of control treatments and lung function in school-age and adolescence. Multimorbidity, 
particularly rhinitis, with or without associated atopy, tended to predict a worse prognosis. 
In the nasal and lung function study, baseline and decongested PNIF correlated with baseline and post-
bronchodilation peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) in school-
aged children, observed independently of rhinitis and asthma diagnosis. The best linear regression model 
for PNIF included the variables PEF, age and gender. In children with allergic rhinitis and asthma, no 
association was found between PNIF and CARATkids scores, except for nasal obstruction self-report. 
Untargeted metabolomics analysis of saliva and urine samples revealed a subset of the spectral areas 
significantly different in the children with allergic rhinitis and asthma, compared to healthy controls. Some 
metabolites contributing to these variables were identified: arginine, taurine, citrate and aspartate (in 
saliva), and quinolinate, butyrate, pantothenate, gluconate, pseudouridine and lysine (in urine). Urinary 
quinolinate, butyrate and pantothenate concentrations correlated with spirometric parameters, while 
quinolinate, gluconate and pseudouridine concentrations correlated with exhaled nitric oxide (FeNO) 
levels. Urinary quinolinate and salivary citrate and aspartate were associated with multiple allergenic 
sensitization. The EBC metabolic profile was found to be highly comparable to the ambient air spectral 
composition. 
Discussion and Conclusions: These were the first population-based nationwide epidemiologic studies 
reporting asthma symptoms prevalence among all pediatric ages, and rhinitis prevalence, its classification 
and association with asthma in the elderly. Our results further support that asthma is a common disease 
in children and the elderly, frequently associated with rhinitis. In early childhood, the presence of 
multimorbidity, particularly rhinitis with or without associated atopy, tended to predict a worse prognosis of 
recurrent wheezing regarding asthma persistence and impaired lung function in later childhood and 
adolescence. These results reinforce the need for a global, integrated care pathway in asthma and 
rhinitis, since early ages. In this integrated assessment, PNIF may provide complementary objective 
information to subjective concurrent control assessment of allergic rhinitis and asthma in school-aged 
children. The results suggested that PEF values should ideally be considered, besides age and gender, 
when interpreting PNIF values in this age group. Exploratory metabolomics revealed differentiating 
subsets of NMR spectral features in saliva and urine associated with allergic rhinitis and asthma 
multimorbidity in children, generating hypotheses to be further analyzed. The results obtained in the EBC 
metabolic profile analysis reinforced the importance of ambient air controls during samples collection and 
the need for analytical procedures to distinguish exogenously originated metabolites in EBC. In summary, 
the results presented in this dissertation added compelling information for an integrated, global 
assessment of asthma together with rhinitis, in clinical practice and in research. We foresee the clinical 
general application of nasal and lung function evaluation in a global airways assessment strategy. The 
differentiating subsets of metabolites found in exploratory metabolomics analysis stimulate further studies 
in order to validate our findings, followed by the identification of molecules/metabolic pathways involved, 
its role in allergic rhinitis and asthma pathophysiology and ultimately the potential as (novel) therapeutic 





Abstract in Portuguese  
Introdução e Objetivos: A asma afeta a vida de várias centenas de milhões de pessoas de todas as 
idades, em todo o mundo. Apesar dos avanços nas últimas décadas, a asma e a sua inerente 
multimorbilidade permanecem um ónus significativo para as pessoas com a doença, para as suas 
famílias e para a sociedade e economia da saúde. Um número elevado de questões permanece por 
responder, abrangendo vários aspetos da doença, relacionados com lacunas no conhecimento científico 
atual, desde a epidemiologia à fisiopatologia e aos cuidados prestados à pessoa com asma. O objetivo 
principal desta dissertação foi contribuir para a abordagem de algumas destas questões relativas à asma 
e a sua associação com a rinite. Em particular, os trabalhos originais visavam: (1) estimar a prevalência 
de asma em Portugal e analisar a sua associação com a rinite em grupos populacionais particularmente 
vulneráveis e sobre os quais há carência de dados a nível internacional - crianças e idosos; (2) identificar 
características para um reconhecimento precoce de asma, através de fenótipos clínicos 
multidimensionais de sibilância recorrente em idade pré-escolar, estabelecidos “sem hipóteses pré-
definidas" e relacionados com a persistência de asma na adolescência; (3) analisar a associação entre 
parâmetros funcionais respiratórios das vias aéreas superiores e inferiores, em conjunto com a avaliação 
subjetiva do controlo da rinite alérgica e da asma, em crianças em idade escolar; (4) explorar estratégias 
inovadoras para identificar características metabólicas associadas ao fenótipo de asma e rinite alérgica 
em crianças, em amostras colhidas de forma não invasiva. 
Métodos: Esta dissertação baseou-se em três tipos de estudos: 
1. Estudos transversais, baseados na população nacional, de cidadãos que viviam em Portugal, tendo 
sido aplicados questionários por entrevista, usando procedimentos padronizados, para a obtenção de 
dados epidemiológicos relativos à asma e à rinite. Para o estudo pediátrico, foram analisados os dados 
de todos os indivíduos com idade inferior a 18 anos que participaram no estudo INAsma (estudo por 
entrevista telefónica, de base populacional, nacional, para estimar a prevalência de asma em Portugal). 
O estudo dirigido aos idosos foi desenhado para estimar a prevalência de rinite em adultos com 65 anos 
ou mais, residentes em Portugal continental, tendo sido os dados colhidos por entrevista direta; 
2. Estudo prospetivo de coorte de crianças com idade inferior a 7 anos com sibilância recorrente, 
avaliadas sistematicamente em pontos de tempo específicos, até 13 anos de seguimento. Foram 
desenvolvidos modelos de regressão logística multivariável para persistência de asma na adolescência, 
com base em respostas a questionários e resultados de testes cutâneos por picada. Os fenótipos 
clínicos foram identificados por análise de agrupamento das variáveis (cluster), selecionadas com base 
na análise de regressão logística, e comparados a respeito da persistência de asma, uso de tratamentos 
de controlo e avaliação funcional respiratória em idade escolar e na adolescência; 
3. Estudo transversal, caso-controlo, de crianças em idade escolar, com rinite alérgica e asma, e 
crianças saudáveis (amostra emparelhada para a idade e género), avaliadas no que diz respeito a: 
 - Análise laboratorial funcional respiratória, i.e., avaliações sequenciais do débito inspiratório máximo 
nasal (PNIF) antes e após a aplicação de vasoconstritor tópico nasal, e espirometria com prova de 
broncodilatação. O teste de controlo da rinite alérgica e da asma para crianças (CARATkids) foi utilizado 
para a avaliação subjetiva do controlo destas doenças. As associações entre os parâmetros de avaliação 
funcional respiratória e de controlo subjetivo foram analisadas usando modelos de regressão linear 
múltipla. 
 - Análise laboratorial analítica por espectroscopia de ressonância magnética nuclear (NMR) para análise 
metabolómica não dirigida das amostras de urina e saliva de cada criança. Os dados espectroscópicos e 
clínicos foram analisados estatisticamente, incluindo abordagens multivariável e univariável. 
Adicionalmente foram colhidas amostras de condensado de ar exalado (EBC) de voluntários, em 
conjunto com amostras de ar ambiente da sala de colheitas. As amostras colhidas foram analisadas por 





Resultados: A prevalência estimada de asma ativa em crianças foi de 8,4% (intervalo de confiança a 
95% (95%CI) 6,6%-10,7%). As prevalências estimadas de rinite e de asma diagnosticada por médico em 
idosos foram 29,8% (95CI% 28,4%-31,3%) e 10,9% (95%CI 9,9%-11,9%), respetivamente. Foi 
encontrada uma associação forte entre asma e rinite a nível populacional, tanto nas crianças (odds-ratio 
(OR) 5,2, 95%CI 3,1-8,9), como nos idosos (OR variando de 8,3 95%CI 6,1-11,4 na rinite intermitente 
ligeira, a 39,9 95%CI 27,5-58,0 na rinite persistente moderada-grave). 
No estudo de coorte, a presença de atopia e de rinite em idade pré-escolar foram fatores de risco 
independentes para a persistência de asma na adolescência (OR 11,8 95%CI 4,0-34,6 e OR 10,4 95%CI 
3,7-29,1, respetivamente). Foram identificados três fenótipos de sibilância em idade pré-escolar, que 
foram preditivos para a persistência de asma, uso de medicamentos de controlo e parâmetros funcionais 
respiratórios em idade escolar e na adolescência. A multimorbilidade, em particular a presença de rinite, 
com ou sem atopia, associou-se a um pior prognóstico. 
Na avaliação funcional nasal e pulmonar, observaram-se correlações entre os valores de PNIF pré e 
pós-vasoconstritor e do débito expiratório máximo instantâneo (PEF) e volume expiratório forçado no 
primeiro segundo (FEV1), pré e pós-broncodilatação, observado independentemente da presença de 
rinite e asma. O melhor modelo de regressão linear múltipla para o PNIF incluiu as variáveis PEF, idade 
e género. Em crianças com rinite alérgica e asma, não foi encontrada associação entre o PNIF e a 
pontuação no questionário CARATkids, exceto no que diz respeito à obstrução nasal auto-reportada. 
A análise metabolómica não dirigida em amostras de saliva e urina mostrou um subconjunto de áreas do 
espetro de NMR significativamente diferente nas crianças com rinite alérgica e asma, em comparação 
com crianças saudáveis. Alguns metabolitos que contribuíram para estas áreas do espetro foram 
identificados: arginina, taurina, citrato e aspartato (na saliva), e quinolinato, butirato, pantotenato, 
gluconato, pseudouridina e lisina (na urina). Observou-se uma correlação entre parâmetros 
espirométricos e a concentração urinária dos metabolitos quinolinato, butirato e pantotenato, enquanto a 
dos metabolitos quinolinato, gluconato e pseudouridina estava correlacionada com os níveis de óxido 
nítrico no ar exalado (FeNO). Observou-se uma associação entre a presença de sensibilização 
alergénica múltipla e as concentrações urinárias de quinolinato e salivares de citrato e aspartato. O perfil 
metabólico do EBC foi semelhante à composição espectral do ar ambiente. 
Discussão e Conclusões: Estes estudos epidemiológicos foram os primeiros de base populacional 
nacional que reportaram a prevalência de sintomas de asma em todas as idades pediátricas, bem como 
de sintomas de rinite, sua classificação e associação com asma em idosos. Os resultados reforçaram a 
asma como uma doença comum em crianças e em idosos, frequentemente associada a rinite. Em 
crianças com sibilância recorrente em idade pré-escolar, a presença de multimorbilidade, particularmente 
rinite com ou sem atopia associada, tende a prever um pior prognóstico no que respeita à persistência de 
asma e compromisso da função respiratória em idade escolar e na adolescência. Estes resultados 
apoiam a necessidade de uma abordagem integrada da rinite e da asma, desde idades precoces. Para a 
avaliação funcional respiratória global, o PNIF pode constituir uma medida objetiva complementar à 
avaliação subjetiva do controlo da rinite alérgica e da asma, em crianças em idade escolar. Os 
resultados sugerem que na interpretação dos valores do PNIF nesta faixa etária, os valores do PEF 
devem idealmente ser considerados, para além da idade e do género. A análise metabolómica 
exploratória de amostras de urina e saliva revelou subconjuntos de áreas do espectro de NMR 
associadas à rinite alérgica e asma em crianças, gerando novas hipóteses que necessitam de análises 
suplementares. Os resultados obtidos na análise do perfil metabólico do EBC reforçaram a importância 
do controlo do ar ambiente durante a colheita de amostras e a necessidade de procedimentos analíticos 
que permitam distinguir a presença de compostos exógenos nas amostras de EBC. Em resumo, os 
resultados apresentados nesta dissertação adicionam evidência para uma avaliação global integrada da 
asma em conjunto com a rinite, tanto na prática clínica, como na investigação. Prevemos que a avaliação 
funcional nasal possa ser generalizada na prática clínica, numa abordagem global funcional das vias 
aéreas. O conjunto de metabolitos identificados na análise exploratória metabolómica estimula a 
continuação dos estudos nesta área para validação dos resultados, seguida da identificação das 
moléculas/vias metabólicas responsáveis pelas diferenças encontradas, o seu papel na fisiopatologia da 
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Chapter 1: Introduction 
Asthma affects the lives of several hundred million people around the World, across all age groups
(1)
. 
Patients, their families and governments face high direct and indirect costs, due to healthcare resources 
use, loss of productivity and absenteeism of patients
(2)
. Asthma strongly influences the wellbeing and 
quality of life of patients. Death due to asthma is unbearable but still occurs. A high number of unmet 
needs remain to be resolved, covering many aspects of asthma related to gaps in current scientific 
knowledge, from epidemiology to pathophysiology and patient care. 
 
Asthma definition: a mirror reflecting knowledge and evolution in asthma 
Disease concept definition is of extreme importance. While it strikingly depends on available knowledge, 
disease definition is the driver of both research and clinical outcomes. Asthma is definitely not an 
exception. 
The term “asthma” has been in use for millennia. The concept of asthma described as a medical entity 
exists since the time of Aretaeus about 2000 years ago
(3)
. However, the description of the condition, with 
the constellation of physical findings and signs that are currently recognized as asthma, has been in place 
since the XVII century
(4, 5)
. Asthma definition has suffered significant historical changes overtime and, 
importantly, asthma management progressed aligned with its concept evolution (Figure 1).  
 
 
Figure 1 – The asthma concept historical evolution 
 
The original concept of asthma as a primary disease of airways smooth muscle drove the development of 
bronchodilator drugs, particularly since the beginning of the last century
(5)
. The mainstay of asthma 
treatment was the relief of bronchospasm and its accompanying signs and symptoms of cough, 
wheezing, chest tightness, dyspnea and fatigue. The concept of airway hyperresponsiveness, a hallmark 
of asthma, came later. It is defined as an exaggerated response of the airways to various stimuli resulting 
in airways obstruction. However, the main step in asthma evolution occurred with the characterization of 
asthma as an inflammatory disease. This concept changed the view of asthma from an episodic disease 
of bronchoconstriction into a chronic disease of inflammation, from bronchodilators rescue treatment to 
corticosteroids preventive treatment. Corticosteroids were not generally available for medicinal use until 
the late 1940s. In the early 1950s, anecdotal reports of refractory asthma patients that had a significant 
response to systemic corticosteroids were published
(4)




accepted as the standard therapy both to treat and to prevent asthma exacerbations, and the major 
issues were how to avoid these treatments’ severe side effects for patients requiring long-term medication 
use. The solution to this problem came in the form of inhaled corticosteroids. These were slowly accepted 
and introduced into clinical practice over the next decades and are nowadays the first line preventive 
treatment of asthma in all age groups
(6, 7)
. This change in the paradigm of asthma and its management 
was associated with the falling asthma mortality and disability rates over the last decades
(1, 8-10)
. 
Asthma is not only characterized by bronchoconstriction and inflammation but also by structural changes 
in the airways, generally known as airway remodeling. These features include epithelial mucous 
metaplasia, increased thickness of the subepithelial lamina reticularis, deposition of matrix proteoglycans 
and collagen in the submucosa and between bundles of smooth muscle, increase in smooth muscle and 
proliferation of microvessels
(5)
. Airway remodeling is not fully dependent on inflammation and may be 
present from the pre-symptomatic inception of the disease
(11-13)
. The acknowledgment of the possibility of 
fixed or irreversible airflow limitation in some patients with asthma, recognized as an adverse asthma 
outcome, was another relevant step in the asthma concept evolution
(6)
. 
In the last years, another significant change in the asthma definition took place. One main historical 
reason for some of the current existing gaps on asthma pathophysiologic mechanisms knowledge may 
have relied on disregarding its complexity and defining asthma as a single disease entity. Although the 
heterogeneity of asthma has been recognized for over a century, for instance as “intrinsic” and “extrinsic” 
asthma
(14)
, it was only in 2014 that the Global Initiative for Asthma (GINA) published a new asthma 
syndrome definition: asthma was no longer considered a chronic inflammatory disease of the airways but 
rather a heterogeneous disease, usually characterized by chronic airway inflammation
(6)
. Nevertheless, 
the diagnosis of asthma should still be based on a history of characteristic symptoms patterns and 




Current asthma definition(6) 
      Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. 
      It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest 
tightness and cough that vary over time and in intensity, together with variable expiratory airflow 
limitation. 
 
This more recent change of concept is again driving current research developments into the search for 
asthma phenotypes, i.e., groups of patients that share similar observable characteristics. Most 
importantly, current efforts are to look for asthma endotypes, defined as subtypes of asthma which may 
be clinically overlapping, but each being caused by distinct underlying pathophysiological mechanisms, 
with different treatment and prognosis
(15)
. This may actually lead to different diseases definitions, perhaps 
making the current concept of asthma obsolete in the future. The need for a new approach to the 
classification and management of airway disease through the identification of key causal mechanisms 





Optimal asthma control is the primary current goal of asthma management 
With no established curative treatment, national and international guidelines for asthma management 
have identified that the primary goal of management is to achieve asthma control
(6, 7)
. This consists of two 
domains: symptoms control and reduced future risk of adverse outcomes. These two domains are not 





Asthma symptoms control is classified into three categories (well-controlled, partly controlled and 
uncontrolled), according to daytime and night-time symptoms, activity limitation due to asthma and need 




 Table 1 – Asthma symptoms control levels (adapted from
(6, 7)
) 
Symptoms control level Well-controlled Partly controlled Uncontrolled 





1 to 2 of 
these 
 
3 to 4 of 
these 
Daytime asthma symptoms in ≥2 
days/week? 
Any night waking due to asthma 
or cough? 
Reliever needed for symptoms ≥2 
days/week? 
Any activity limitation due to 
asthma? (adapted to age group) 
n.b., any exacerbation in any week identifies uncontrolled asthma and demands for re-assessment of the 
preventive treatment plan. 
 
Reducing future risk includes three main aspects: minimizing asthma exacerbations, long-term lung 
function impairment and medication side-effects. Asthma management should be adapted to every 
patient in order to maintain asthma control, without exacerbations and with the best possible lung 
function, using the minimum needed medication. Given asthma symptoms characteristic variability, 
asthma management requires regular control assessment, in a close partnership between patients and 
physicians and other healthcare professionals, empowering patients to actively achieve total disease 
control as a goal. Pharmacological and non-pharmacological strategies should be addressed and 
combined in educational plans for asthma management. Prevention and avoidance of risk factors that 
may precipitate asthma symptoms are key elements, as well as multimorbidity control, together with 
stepwise pharmacotherapy (Figure 2). 
 
* For children 6-11 years, the preferred choice is medium dose ICS; # low dose budesonide or beclomethasone associated with 
formoterol used both for maintenance and reliever treatment regime for adolescents and adults. 
Legend: ICS – inhaled corticosteroid, FEV1 – forced expiratory volume in one second, IgE – immunoglobulin E,             
IL-5 – interleukin 5, LABA – long-acting beta-agonist, LAMA – long-acting muscarinic antagonist (tiotropium),         
LTRA – leukotriene receptor antagonist, OCS – oral corticosteroid, SABA – short-acting beta-agonist. 






In selected cases, the new GINA guidelines considers the use of sublingual allergen specific 
immunotherapy for adults
(6)
. Current evidence also supports this treatment by subcutaneous route and its 
use in children, but responses can be specific to extracts and treatment regimens
(6, 18, 19)
. Studies using 
validated tools to assess disease control, standardized outcomes (such as exacerbations) and comparing 
immunotherapy with other pharmacological therapy should bring additional relevant evidence to this field. 
 
 
The global airways disease context 
The need to consider asthma multimorbidity is critical to achieve asthma control. The nose strategic 
position at the entry of the airways justifies its crucial role in lower airways homeostasis. Upper and lower 











Rhinitis is the leading comorbidity in asthma; most patients with asthma have rhinitis and up to 40% of 
patients with rhinitis have asthma
(6, 22)
. Chronic rhinosinusitis with/without nasal polyps is also associated 
with asthma
(24)
. Both rhinitis and rhinosinusitis clearly influence asthma control
(6, 22)
. Failure to consider 
the treatment of coexisting rhinitis as essential to the management of asthma may impair clinical control 
of the latter and has been associated with high frequency of asthma-related hospitalization and 
emergency department visits
(6, 21, 23)
. The close relationship between asthma and rhinitis has been 
recognized by the World Health Organization, namely through the Allergic Rhinitis and its Impact on 
Asthma (ARIA), and catalyzed by the Global Alliance against Chronic Respiratory Diseases (GARD) 
initiatives
(22, 25)
. Current available evidence mostly regarding adults supports that patients presenting with 
chronic airway symptoms should be specifically and actively asked about upper and lower respiratory 








Although the interaction between chronic upper and lower airway inflammation has primarily been studied 
in allergic individuals, not only allergic but also infectious or non-allergic non-infectious rhinitis can be 
involved (Figure 4). Currently, rhinitis is defined as inflammation of the mucous membrane of the nose 
and is characterized by classical symptoms of nasal pruritus, sternutation, rhinorrhea and/or nasal 
obstruction
(22, 23)
. At least two nasal symptoms should be present during two or more consecutive days for 
more than one hour on most days
(23)
. 
Infectious rhinitis is often an acute and self-limiting disease caused by a virus, usually known as common 
cold. However, infectious rhinitis may have a more prolonged disease course; discolored secretions 
and/or crust formation are clinical landmarks of this rhinitis subtype
(26)
. 
Allergic rhinitis is considered when nasal symptoms are elicited by immune mediated mechanisms after 
allergen exposure, such as of house dust mites, pollens, molds or pets. Systemic atopy is usually 
investigated by skin prick tests or serum specific immunoglobulin (IgE) against allergens. Local allergic 
rhinitis has also been identified, as the occurrence of allergic rhinitis symptoms in patients with exclusively 
local production of allergen specific IgE antibodies in the nasal mucosa
(26, 27)
. 
Non-allergic non-infectious rhinitis involves a heterogeneous group of patients suffering of rhinitis without 
clinical signs of infection and allergic inflammation. In reality, more than one etiologic factor may coexist in 
the so-called mixed rhinitis
(26)
. 
Asthma has been associated with allergic and non-allergic rhinitis subtypes but a distinct endotype of 



















 Table 2 – Allergic rhinitis definition and classification (adapted from 
(22, 23)
) 
Allergic rhinitis definition 
      Inflammation of the mucous membrane of the nose, characterized by nasal pruritus, sneezing, 
rhinorrhea and/or nasal obstruction, elicited by immune mediated mechanisms after allergen 
exposure. 
 
Allergic rhinitis classification 
Duration Nasal symptoms duration 
     Intermittent Lasting <4 days/week or <4 consecutive weeks 
     Persistent 
 
Lasting for at least 4 days in a week and for >4 consecutive weeks 
Severity 
Sleep disturbance, impairment of daily activities, leisure and/or 
sports, impairment of school or work, and troublesome 
symptoms 
     Mild 
 
None of the above 
     Moderate-Severe 
 
At least one of the above is present 
 
Allergic rhinitis pharmacologic treatment is based on antihistamines in all rhinitis classification categories, 
and topical nasal corticosteroids are the mainstay of rhinitis control in persistent rhinitis and in all 
moderate-severe presentations
(22)
. Allergens and irritants avoidance, nasal hygiene and correct use of 
topical nasal drugs are essential measures for successful rhinitis control. If accurately prescribed and 
monitored in selected cases, allergen specific immunotherapy may allow prolonged symptoms remission 
and reduce the need for medication: through its immunomodulatory effect it may modify the natural 
history of the allergic disease, decrease the emergence of new allergic sensitizations, as well as the 
incidence of asthma in children with allergic rhinitis
(23, 30-33)
. Other pharmacologic treatments in allergic 
rhinitis include vasoconstrictor drugs (for short-term periods, useful for the relief of nasal obstruction) and 
leukotriene receptor antagonists (anti-inflammatory optional controller therapy)
(22)
.  
Rhinitis might not appear to be serious per se because, without complications or associated diseases, it is 
not linked to severe life-threatening morbidity. However, rhinitis is regarded as a public health problem; its 
prevalence, burden and costs are substantial
(22, 34-36)
, even without adding all possible complications of 
the disease and commonly associated conditions, such as asthma. 
In spite of the advances with the development and dissemination of guidelines for the management of 
asthma and associated diseases
(6, 7, 22)
, national and international surveys continue to reveal inadequate 
control, as is the case in Portugal
(37-44)
. Asthma and its multimorbidity continue to impart a significant onus 
on individuals with the disease, families of the affected and society and health economies. Identifying 
current unmet needs and establishing strategies for their resolution are important to contribute to the 






Unmet need: asthma prevalence and its association with rhinitis in the extremes 
of life 
Despite the fact that asthma has been recognized since more than 2000 years ago, it was only in the last 
four decades that asthma has become a serious health concern. This was precipitated by an epidemic of 
asthma deaths in the late 70s, which occurred in different places, mainly New Zealand, Australia, The 
United Kingdom, Canada and the United States of America. With improved asthma patients care, 
mortality rates have fallen worldwide over the last three decades, but asthma remains a major cause of 
chronic disability, affecting all generations
(1, 8-10)
. 
Chronic respiratory diseases, including asthma and rhinitis, represent a global concern. The World Health 
Organization recommends assessing population needs to better define adequate health policies
(45)
. 
Epidemiologic studies at the population level have been crucial for this assessment. Over the last 
decades, large international surveys have been conducted using standardized methodology to estimate 
asthma symptoms prevalence, including the European Community Respiratory Health Survey (ECRHS), 
the International Study of Asthma and Allergy in Childhood (ISAAC) and the Global Allergy and Asthma 




. While the ISAAC study focused on children (aged 6-7, 9-
11 and 13-14 years)
(47, 48)
, the ECRHS assessed the prevalence of asthma symptoms in the general 
population aged 20 to 44 years
(46)
. The ECRHS was conducted in different countries (mostly in Western 
Europe) for the first time in 1991-1994. The GA
2
LEN survey included a broader age group (15-74 years) 
in 15 European countries in 2008/2009
(49)
. All these studies have found wide variations in the prevalence 
of asthma symptoms in the different countries: more than 5% of any investigated population suffered from 
asthma; in some regions, this percentage was much higher. The reasons for the variability in asthma 
frequency across the world and the sharp rise in its prevalence in the last decades have been mostly 
associated with environmental factors and lifestyle, which have undergone profound changes in a 
relatively short period of time (including changes in housing design, exposure to outdoor and indoor 
pollutants, microbial exposure, family size and childcare arrangements, diet and sedentary life style). 
However, the effect of specific environmental exposures can be different amongst individuals with 
different genetic predispositions or be modified by co-exposures, and knowledge about the underlying 
cause(s) of asthma epidemics remains elusive. 
Portugal participated in the three surveys mentioned before
(46, 49, 50)
, but only some cities were included 
and the results were limited to the predefined age groups. Additionally, nationwide health surveys took 
place
(51, 52)
, but their focus had not been asthma and therefore a standardized methodology to provide 
data on asthma symptoms wasn’t used. The Portuguese National Asthma Survey – Inquérito Nacional 
sobre Asma (INAsma) was the first population-based nationwide epidemiological study that estimated 
asthma prevalence in Portugal in all age groups
(53)
. It was conducted in 2010 and included a large 
representative sample of the Portuguese population. The estimated prevalence of lifetime asthma 
(defined as positive answer to the question “Have you ever had asthma?”) and current asthma (defined 
as self-reported lifetime asthma and “wheezing”, “waking with breathlessness” or “having an asthma 
attack” in the last 12 months) were 10.5% (95%CI 9.5%-11.6%) and 6.8% (95%CI 6.0%-7.7%), 
respectively
(53)
. This study further showed a strong association of asthma with rhinitis and rhinosinusitis, 
in agreement with the known risk of chronic disease of upper airways in asthmatics
(53)
. These data were 
important to provide accurate estimates of asthma at the national level. Still, two particularly vulnerable 
and internationally data-lacking populations remained on the extremes of life: the children and the elderly. 
Differences in symptoms and in asthma and rhinitis frequencies could be expected in these age groups, 
possibly due to age-related physiological changes including structural and functional airway changes, 
immune system development/senescence, or different lifetime environmental exposures. The concept of 
the “allergic march” described the progression from atopic dermatitis in infancy to subsequent asthma and 
allergic rhinitis in later childhood and adolescence
(54)




frequencies of these diseases. Comorbidities and medication intake could also account for some 
differences in these two population groups. A better understanding of the asthma and rhinitis impact 
within specific childhood and elderly age groups is important to reduce the diseases burden in these 
population groups. 
The ISAAC study had changed our knowledge about worldwide prevalence of asthma-related symptoms 
in children. Portugal had been involved since this project’s early beginning in 1991 and participated in all 
study phases: phase I in 1994/1995; phase II in 2000/2001 and phase III in 2002. However, again, neither 
ISAAC, nor other previous studies performed in Portugal estimated the prevalence of asthma across all 
pediatric ages (<18 years) or among a representative nationwide sample. Internationally, nationwide 
studies on the prevalence of asthma across the entire pediatric population had only been reported in 
Germany and the United States of America
(55, 56)
, and no study had reported the prevalence of asthma-
like symptoms, other than wheezing, across all pediatric ages. 
On the other extreme of life, elderly-targeted, population-based studies considering asthma and rhinitis 
were scarce, although the greatest burden of asthma deaths occurred among elderly subjects
(10, 56-58)
. In 
recent decades, there was a significant increase in the elderly population, both in Europe and the United 
States of America. Studies specifically addressing this age group were needed for a proper analysis of 
asthma and its association with rhinitis in geriatrics, allowing better knowledge about this population 
subgroup needs and raising awareness towards effective disease control also in this age group. 
Nationwide epidemiologic data on rhinitis in the elderly did not exist before at the international level and 
no population-based study had ever analyzed the association between asthma and rhinitis symptoms and 
severity in this age group.  
 
 
Unmet need: definition of early childhood wheezing phenotypes related to asthma 
persistence 
Knowledge on the frequency of the disease at the population level, the characterization of its symptoms 
and its multimorbidity is important to increase knowledge on the disease and to better plan strategies 
aiming to reduce its burden. Yet, in order to achieve this aim, an early recognition of the diagnosis is 
essential. 
Most asthma cases begin during childhood. Wheezing in early childhood is among the most frequent 
respiratory symptoms
(59-61)
. When evaluating a child with wheezing, it is important to exclude other causes 
than asthma, from aspiration to respiratory infections or other pulmonary, cardiac or even 
gastroesophageal reflux diseases (Table 3). 
After excluding these disorders, much heterogeneity remains in recurrent wheezing, which may be 
associated with very distinct prognosis. Most children with early wheezing become symptom-free in later 
childhood and adolescence; wheezing is transitory and the children fully recover without sequels, having 
excellent prognosis. On the other hand, early-onset wheezing is also associated with persistent asthma 
symptoms in adulthood and, with more severe, persistent lung function impairment
(62-64)
. Thus, 
distinguishing early wheeze phenotypes to predict long-term asthma persistence is of major clinical 
relevance. The recognition of such distinct outcome groups is valuable for informed counselling to parents 
and a prerequisite for phenotype-specific management, identifying early those children who require closer 







 Table 3 – Differential diagnosis of asthma in children 
Differential diagnosis 
(non-exhaustive list of diseases that may manifest with wheezing other than asthma) 
Respiratory infection, including bronchiolitis, bronchitis, laringotracheobronchitis 
Aspiration of foreign body, associated with neuromuscular disorders, fistulae (e.g. tracheoesophageal) 
Gastroesophageal reflux disease 








Interstitial lung disease 
Cardiovascular disease, including left-right shunt, heart failure, vascular ring 
Mediastinal mass, including aneurysm, tumor, goiter 
 
Characteristics that favor differential diagnosis 
Sudden onset 
Early age of symptoms onset 
Context: exposure to infectious agents, irritants, relation to food/drink intake 
Systemic signs and symptoms: weight loss, failure to thrive, asthenia, anorexia, night sweats 
Recurrent / severe infections 
Hemoptysis  
Atypical disease progression: persistent signs and symptoms; symptoms not related to common triggers 
such as exercise, allergen exposure, stress, cold; inadequate therapeutic response 
Asymmetric signs 
Lack of personal or family history of rhinitis, atopic dermatitis, food allergy or family history of asthma 
 
 
The largest contributions to identify early childhood wheeze phenotypes came from longitudinal birth-
cohorts
(60, 62, 64-67)
, and from mostly moderate to severe wheezing cohorts studies
(68-70)
. However, different 
studies originated distinct phenotypic classifications. Many categories of recurrent wheezing were based 
on predefined hypotheses and limited to single disease dimensions. Therefore, its application to different 
age groups or incorporation of other characteristics was restrained. Furthermore, phenotype 
classifications based on temporal criteria have limited clinical use, since such groups can only be 
established retrospectively. In 2008, a European Respiratory Society Task Force recommended 
distinguishing between two wheezing phenotypes with a differentiated approach to preventive treatment: 
episodic viral wheeze and multiple-trigger wheeze
(71)
. However, this classification has been revised due to 
difficulties in including children in mutually exclusive groups and to the rapid symptom pattern change 
over time
(72)
. The international consensus group review acknowledged that this classification of wheeze 
was a relatively poor predictor of long-term outcome
(72)
.  
In more recent years, multivariable statistical methods have been proposed to facilitate the unbiased 
identification of relevant phenotypes
(73)
. Such groups may not be directly observable and must be 




data have the advantage of avoiding the need to define phenotypes by the onset of wheeze at a given 
age or other pre-specified criteria, and thus are classified as “hypothesis-free” methods. Another benefit is 
to simultaneously consider several disease dimensions. Since there is no specific single indicator that 
accurately predicts the development of asthma or identifies high risk children or the disease course of an 
asthmatic patient, it is most likely that the combination of multidimensional features will be necessary to 
achieve these aims. These methods tend to have a broader application, better allowing comparisons in 
different population settings. Application of such “unbiased” statistical methods “without predefined 
hypothesis” to distinguish groups of patients is important to validate previous phenotypic classifications. 
In brief, “unbiased” phenotypic classifications derived exclusively from data can be complementary to 
groups defined a priori or based on directly observable criteria. The identification and characterization of 
distinct wheezing phenotypes with different prognosis, by the comprehensive analysis of longitudinal 
datasets are important to implement interventional measures to reduce the asthma burden since pediatric 





Unmet need: biomarkers in allergic rhinitis and asthma multimorbidity in children 
According to the current paradigm, asthma should not be regarded as a single disease, but rather a 
syndrome of complex, multiple, overlapping “subtypes”, which are probably distinct since their early 
beginning. The asthma syndrome is multifactorial, with genetic, lifestyle and environmental components 
interaction. Under the umbrella of current asthma definition, age of onset of symptoms, associated 
diseases, symptoms presentation and its triggers, lung function impairment, inflammation patterns and 
airway remodeling features can differ and be used to define different phenotypes. The prognosis is also 
distinct as well as the response to therapy. Despite all efforts to define specific asthma phenotypes, no 
single consensual phenotypic classification of asthma exists as, to date, no strong relationship has been 
found between specific pathological features and particular clinical patterns or treatment responses
(6)
. 
Nevertheless, “allergic asthma” (as defined by GINA) is the most commonly recognized phenotype
(6)
. 
“Allergic asthma” is characterized by eosinophilic airway inflammation and airway hyperreactivity driven 
by adaptive T helper (Th) 2 cells that are stimulated by dendritic cells, under the influence of epithelial 
cytokines interleukin (IL)-33, IL-25 and thymic stromal lymphopoietin, to produce IL-5, IL-13 and IL-4
(75)
. 
The latter drives IgE synthesis, which has the potential to activate mast cells and basophils. Mast cells 
can infiltrate the airway, contributing to bronchial hyperreactivity and also plasma extravasation. 
Moreover, the presence of IgE on dendritic cells primes naive T cells for Th2 differentiation and lowers 
the atopic individual’s threshold to mount allergen-specific T cell responses. Through the production of IL-
5, Th2 cells drive eosinophils development, survival and activation. Upon activation, eosinophils undergo 
cytolysis and release extracellular deoxyribonucleic acid traps that can lead to high local concentrations 
of eosinophilic toxins that can damage structural cells of the lung
(76)
. These traps can also contribute to 
the thick mucus, with the characteristic Charcot-Leyden crystals. Via IL-13, Th2 cells can also cause 
goblet cell metaplasia producing mucus, airway hyperreactivity and extravasation of inflammatory cells. 
Interleukin-13 activated epithelial cells produce angiogenic growth factors and periostin that promotes 
myofibroblast proliferation
(77)
. The disrupted epithelial barrier also contributes to remodeling through 
epidermal growth factor driving the production of transforming growth factor beta and consequent 
deposition of collagens, laminin, tenascin and proteoglycans. Eosinophils are also an important source of 
transforming growth factor beta. Besides this long considered Th2 disease, it is now known that some 
asthmatic inflammation is neutrophilic, with predominant mixed Th1 and Th17 cytokine milieu, and that 
some eosinophilic inflammation is rather controlled by type 2 innate lymphoid cells producing IL-5 and IL-





populations of different cell types and cytokines are found in the airways and a dynamic overlap of these 
mechanisms is probably occurring
(75)
. 
The predominant “allergic asthma” phenotype typically begins during childhood and is associated with 
other allergic diseases, mainly allergic rhinitis
(6)
. This well-known link between asthma and allergic rhinitis 
has recently been supported by large-scale unbiased clustering at the population level in children, 
suggesting that undisclosed mechanisms underlying these diseases need to be investigated considering 
an “allergic multimorbidity” cluster
(28, 29)
. At the clinical level, this further supports an integration of care 
pathways in these allergy-related diseases. 
 
Integrating care pathways with biomarkers – adding nasal function in concurrent evaluation of 
allergic rhinitis and asthma control in children? 
The recognition of the close relationship between asthma and rhinitis at the global level has resulted in a 
call for a change in patients care, with the combined approach for asthma and its multimorbidity, 
particularly allergic rhinitis. In this context, the need for a simple assessment tool that could be readily 
used in clinical practice has been overcome with the development of the Control of Allergic Rhinitis and 
Asthma Test (CARAT)
(78-80)
. This questionnaire, designed by a group of Portuguese 
immunoallergologists, respiratory physicians, family physicians and pediatricians, was the first to assess 
the control of both diseases concurrently. It has been validated and adopted in different languages
(81)
. 
Furthermore, website and smartphone applications have been developed and a free open model 
distribution was adopted. A pediatric version of this test – the CARATkids – has also been developed and 
validated
(82, 83)
. The use of validated subjective scoring tools is nowadays highly recommended for the 
subjective evaluation of rhinitis and asthma control
(6, 22, 84, 85)
. 
Adding an objective measurement to subjective scores can be useful to improve disease control. One of 
the main complaints in allergic rhinitis is nasal obstruction
(23, 85, 86)
. It has been previously shown that 
subjective and objective measures of nasal patency do not correlate well
(87)
. Thus, it is recommended that 
the assessment of a patient suffering of nasal obstruction should be based upon both measures
(84, 85, 88)
. 
However, no previous data existed on the association between CARAT questionnaires scores and 
objective measures of nasal patency. 
Nasal airflow can be objectively and easily assessed using a nasal peak flow meter. Peak nasal 
inspiratory flow (PNIF) is the simplest validated measure of nasal function
(84, 85)
, which has been 
successfully used for the objective evaluation of rhinitis and its control
(89-92)
, including in children
(93, 94)
. 
Reference values for the pediatric population have been published, but no data was previously available 
on PNIF values after decongestion
(95-99)
. It is important to measure PNIF values before and after 
decongestion to elicit the role of mucosal swelling
(84, 85)
. 
The impact of lower airway patency on PNIF also needs to be considered
(84, 85, 100-102)
, especially when 
addressing patients with the rhinitis and asthma multimorbidity phenotype. This had seldom been 
analyzed in pediatric age. A bivariate correlation between baseline PNIF and peak expiratory flow (PEF) 
had been described in healthy children
(98)
. Nevertheless, since a continuous increase in PNIF values has 
been consistently reported with children’s age
(95-99)
, it is important to exclude that the observed 
association between PNIF and PEF is not a simple reflection of the normal growth (i.e., older children 
have larger airways and correspondingly higher nasal airflow). Most studies in children also describe an 
association between PNIF and height, weight and gender
(96-98)
. Analyzing the association between PNIF 
and lower airway patency in children using multivariable models is needed for a more accurate use of 
nasal airflow assessment in this age group, possibly contributing with additional information regarding 










“Unbiased” molecular profiling – contributing to the link between clinical phenotypes and disease 
endotypes? 
The diversity of asthma phenotypes led to the hypothesis of existing distinct undisclosed 
pathophysiological mechanisms, but presently no agreed criteria upon asthma endotypes exists. 
Exploratory molecular profiling using high-throughput “omics” approaches may support the “unbiased” 
characterization of clinically defined asthma phenotypes at the molecular level and thus help to step 














Presently, asthma pharmacologic treatment continues to be based on the intrinsic asthma severity, with 
drugs added on the basis of disease control, approximate to a “one size fits all” regime. Although this 
approach benefits many patients, its efficacy varies widely at the individual level. Asthma management is 
still mostly “reactive” (added treatments after loss of asthma control) rather than “proactive” (acting earlier 
to prevent disease burden), although more emphasis is now given to future risk reduction
(6, 7)
. In this 
setting, biomarkers are needed to innovate asthma management. Currently available and most promising 
biomarkers have been discussed elsewhere (author publication – full text available in the Attachments 
section – number 2)
(104)
. 
Uncovering the mechanisms underlying different endotypes in the “asthma syndrome” would improve 
knowledge on the natural history of these conditions and ideally lead to mechanism-specific 
pathophysiologic biomarkers and interventions for disease prevention and treatment with effective 
personalized therapies. 
The complexity of asthma can rely on several pathophysiological mechanisms, which can interact and 
may not be present in all patients or at all times. Multivariable measurements are most likely needed to 
capture asthma complexity, which may yield more useful information than existing single or even panels 
of combined biomarkers
(104)
. In this context, the “omics” disciplines, combining the high-throughput 
analytic techniques with bioinformatics, have recently emerged as important tools in medical research. 
These provide comprehensive, broad molecular analysis in biological specimens and may enable the 
detection of multivariable composite biomarkers of the disease. Among the “omics” disciplines, 
metabolomics is the closest to phenotype expression, aiming at the universal analysis of metabolites in 
biological specimens (Table 4; author publications – full texts available in the Attachments section – 















Metabolomics Large-scale study of metabolomes that aims at the universal analysis of low molecular 
weight (typically <1500Da) metabolites in biological specimens. 
Metabolome  Complement of naturally-occurring and exogenous metabolites within biological 
systems. 
Metabolite  Substrate and product of metabolism that drive essential cellular functions, such as 
energy production and storage, signal transducing and apoptosis. 
Metabolism  Chemical reactions that occur within an organism to sustain life. The reactions are 
globally divided into two categories: catabolism (the breakdown of organic matter to 
produce energy) and anabolism (the construction of molecules from smaller units). 
Targeted 
metabolomics 
Metabolomics methods developed and optimized to measure the concentrations of a 
predefined set of metabolites of interest. These methods allow higher sensitivity and 
selectivity and may provide analytical validation to results from untargeted analysis. 
Untargeted 
metabolomics 
Metabolomics methods aimed at measuring the broadest range of metabolites present 
in an extracted sample without a priori knowledge of the metabolome. 
Mass 
Spectrometry 
One of the main analytical platform used for metabolomics analysis that measures the 
masses of molecules and their fragments (mass-to-charge ratio (m/z) of ions that are 
formed by inducing the loss or gain of a charge from neutral species) to determine 




One of the principal analytical techniques used for metabolomics analysis that exploits 
the magnetic properties of the atom nuclei (absorption and re-emission of 
electromagnetic radiation) to obtain physical, chemical, electronic and structural 
information about molecules. 
 
 
In contrast to transcriptional, translational and post-translational changes, metabolites have the distinct 
advantage of being more proximal markers of disease processes and to easily capture the effect of past 
exposures. The profiling of metabolites in biofluids, cells and tissues allows an instantaneous snapshot of 
a biological system status, reflecting the net results of genetic and environmental interactions, which are 
two critical dimensions in asthma. 
Classically, the molecular characterization of asthma has been driven by hypotheses generated by 
investigators. This strategy relies on a specific number of analytes and previously set criteria to classify 
the disease. The complexity of pathophysiological processes underlying asthma rendered a broad 
spectrum of involved metabolic pathways and products, resulting in an overwhelming choice of potential 
biomarkers and targets for disease treatment
(104)
. This classical approach for the molecular 
characterization of asthma may be further complemented with a different strategy. For instance, 
untargeted metabolomics has no metabolite identification before sample analysis and provides a broad 
and unsupervised multivariable description of metabolites in a given sample (Table 4). As such, it may 
contribute to “unbiased”, data-driven metabolic profiling of asthma. The utility of such characterization can 
be to identify potential biomarkers for asthma or asthma “subtypes” and to improve understanding of the 
pathophysiology of asthma, with a “hypothesis-free” strategy
(107)
.  
Mass spectrometry and NMR are the two principal analytical platforms used for metabolomics analysis 
(Table 4). These two techniques are complementary and different molecules can be identified. 
Furthermore, the NMR is highly reproducible and usually requires less sample preparation but has lower 
sensitivity, while liquid or gas chromatography coupled with mass spectrometry is highly sensitive and 






The metabolome also highly depends on the sample source (Table 5). 
 
 Table 5 – Pros and Cons of main biomarker sample sources in asthma metabolic profiling studies
(104)
 
Biomarker source Pros  Cons  
Lung biopsy / 
bronchoalveolar 
lavage fluid 
More direct airway evaluation 
Molecular, cellular and tissue 
biomarkers 
Invasive 
Several medical contraindications 
Rescue medication / procedures needed 
Non-repeatable in many patients 
Expertise and experience required for procedure 
Procedure itself may induce changes in airways 
Induced-sputum More direct airway evaluation 
Semi-invasive 
Molecular and cellular biomarkers 
Very difficult in young children 
Contraindicated in severe bronchoconstriction / 
active cardiovascular disorders 
Rescue medication / procedures needed 
Non-repeatable over short time-period (<12-18h) 
Procedure itself may induce changes in airways 
Require expertise, expensive and time-
consuming specialized lab assays 
Exhaled breath More direct airway evaluation 
Totally non-invasive 
Point of care technology 
May be collected across all ages 
May be collected in severe patients 
Allows serial measurements 
Highly variable matrix 
Highly diluted soluble markers (very low 
concentrations) 
Blood Minimally-invasive 
Molecular and cellular biomarkers 
May be collected across all ages 
May be collected in severe patients 
Allows serial measurements 
Not directly reflecting the airways 
 
Urine / Saliva Totally non-invasive 
May be collected across all ages 
May be collected in severe patients 
Allows serial measurements 
Not directly reflecting the airways 
 
Metabolomics applied to lung tissue may hold the best chance of obtaining relevant data for detecting 
specific asthma endotypes, given the direct airways evaluation. However, obtaining lung tissue requires 
invasive procedures that are difficult to set up. Biomarkers need to be developed in accessible 
compartments that can be analyzed relatively easy and repeatedly. More indirect samples such as blood 
or even urine samples have been shown to be useful for metabolic profiling biomarker identification and 
even underlying mechanisms research in asthma
(105-108)
. These preliminary metabolomics data reinforced 
these matrixes as surrogates of pathophysiologic processes that occur in asthma. Urine is particularly 
easily obtained non-invasively and it is metabolically interesting as an end-product sampling of metabolic 
activity of a given organism
(109)
. Recently, liquid chromatography combined with mass spectrometry was 
applied to a pilot study of saliva samples in asthmatics, also demonstrating the potential to discriminate 
asthma
(110)
. Exhaled breath analysis is also very appealing, given the easy and repeatable sampling that 
cope with asthma dynamic changes. In fact, exhaled breath can be sampled in a gaseous (vapor) or 
liquid (exhaled breath condensate - EBC) state, in fully non-invasive ways across all age groups. Exhaled 
breath potentially reflects the airways
(104)
. However, when measuring exhaled molecules as biomarkers of 
physiological processes, one should consider that many compounds in exhaled breath may have 
exogenous origins. So far, the search for useful molecular biomarkers in this matrix has been hampered 
by methodologic difficulties mainly dealing with samples stability, very low molecular concentrations, low 
sample volumes, variability and lack of sampling and analyzing methods standardization
(104, 111)
. EBC has 





volatile compounds. It is obtained by cooling exhaled air and is thought to reflect the composition of the 
airway lining fluid. Although methodological recommendations for exhaled breath sampling and analysis 
have been published
(112, 113)
, the procedures for exhaled breath collection and biomarker detection are not 
fully systematized and there is significant heterogeneity between different working groups, hampering 
results comparisons
(112, 113)
. This heterogeneity in procedures becomes even more important with the 
growing number of “omics” studies using such multivariable analytical techniques as NMR and mass 
spectrometry. Addressing these issues of procedures standardization, together with metabolite 
identification and external validation will be critical in order to achieve robust conclusions that can be 
translated into clinical practice, using these high-throughput technologies at their full potential
(105, 106)
. In 
addition to biomarkers identification, relating metabolites to their biological role may bring relevant data 




Although metabolomics in asthma is at its early infancy, novel biological insights have already been 
gained
(105, 106)
. Currently, several clinical studies using untargeted metabolomics approaches have yielded 
distinct results and suggested a broad number of metabolites associated with asthma. Common altered 
individual metabolites identified by different research groups include amino acids, lipids, purines, salts 
and alcohols (Table 6).  
 
Table 6 – Metabolites associated with asthma in at least two independent studies in humans 
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Taurine  Organic sulfonic acid 
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Acetate Carboxylic acid  NMR
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Formate Carboxylic acid NMR
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Methanol Organooxygen compound 
(alcohol) 
NMR






































Legend: * - Classification according to “The human metabolome database” (http://www.hmda.ca, accessed in April 2018); EBC – exhaled breath condensate; MS – mass 





Metabolites level changes depended on the analyzed matrix. For instance, low arginine plasmatic levels 
have been found in asthmatics
(118)
, but this metabolite levels were higher in EBC of patients with asthma 
than healthy subjects
(117)
. More interestingly, these studies suggested that several metabolic pathways 
were altered in asthma. This preliminary data supported that further insights could contribute to increased 
knowledge in asthma. Despite very reductive, Figure 6 aims to represent the main metabolic pathways 
suggested to be significantly altered in asthma in at least two independent untargeted metabolomics 
studies in humans and also supported by targeted analyses. In particular, there was considerable 
consistency in identifying amino acids metabolism as significant. Amino acids can have antioxidant 
functions; in particular glycine, glutamine and glutamate may have potentially protective effects, whereas 
phenylalanine can have adverse effects
(108)
. Oxidative stress (resulting from an imbalance between 
oxidants and antioxidants in favor of oxidative states) has a significant role in asthma pathophysiology 
and lung damage
(124)
. Oxidized compounds that significantly distinguished asthmatics from healthy 
subjects have been identified in untargeted metabolomics studies
(125)
. Metabolic pathways associated 
with oxidative stress in asthma involved not only amino acids, including essential components in 
glutathione metabolism, but also lipids peroxidation
(126)
. The influence of the microbiome on asthma 
pathogenesis has recently gained much interest with novel evidence being added, namely regarding short 
chain fatty acids produced by intestinal microbiota and its role in oxidative stress and inflammation
(127)
. 
Changes in the energy metabolism with increased tricarboxylic acid-cycle metabolism have been 
associated with an enhanced requirement for energy in asthma exacerbations and uncontrolled asthma, 
with a more hypoxic, acidic and oxidizing environment. In this setting, purine metabolism has also been 
identified in untargeted metabolomics studies in humans. Although adenosine is well-known for its 
bronchoconstrictor and inflammatory effects, not only adenosine but also other related molecules have 
been detected as significantly altered in asthma, including deoxyadenosine, adenosine monophosphate 
and inosine
(114, 115, 117)
. Finally, metabolites related to the epigenetic pathways were also reported
(117, 118)
. 




There were also a number of non-replicated results. However, current evidence is insufficient to 
determine whether these represent spurious findings or reflect the substantial heterogeneity in the 
different studies. The metabolome can highly depend on the sample source, the analytic technique, its 
intrinsic coverage and data analysis, together with study design, besides the target population, 
particularly in complex heterogeneous diseases such as asthma. The primary aim of most metabolomics 
studies was to examine the differences between asthma cases and healthy controls, with a very few 
number of studies examining particular clinical asthma phenotypes. However, exploring the molecular 








         Figure 6 – Simplified example of metabolic pathways suggested to be altered in asthma in at least two independent untargeted metabolomics 
studies in humans (the net utilization or production of metabolites is dependent on cell type and location in the cell; arrows do not necessarily represent direct 
metabolism) Legend: ATP – adenosine triphosphate; ADP – adenosine diphosphate; AMP – adenosine monophosphate; dADP – deoxyadenosine diphosphate; 










Chapter 2: Aims 
The main global objective of this dissertation was to contribute to unveil features for early diagnosis 
and recognition of asthma in the global airways disease context, advancing in the integrated control 
assessment and exploring innovative strategies for the molecular characterization of allergic rhinitis 
and asthma to step forward into endotypes, ultimately aiming to reduce the multimorbidity associated 
burden. 
In particular, the original work aimed to address existing unmet needs in asthma and its link with 
rhinitis: 
 nationwide, estimating asthma prevalence and analyzing its association with rhinitis in 
particularly vulnerable, internationally data-lacking populations – the children and the elderly 
(Outputs 1 to 3); 
 clinically, identifying multidimensional early childhood wheezing clinical phenotypes related to 
asthma persistence until adolescence (Output 4); 
 functionally, analyzing the association between nasal airflow and lower airway patency, 
together with the subjective evaluation of allergic rhinitis and asthma control in school-aged 
children (Output 5). 
 molecularly, exploring broad, data-driven differentiating metabolic features of childhood 
allergic rhinitis and asthma multimorbidity in non-invasively collected samples (Outputs 6 and 
7); 
 
Specific primary aims: 
Output 1: To estimate the prevalence of current asthma prevalence and asthma-like symptoms in the 
pediatric population (<18 years) living in Portugal. 
Output 2: To estimate the prevalence of rhinitis in the population aged 65 years or above living in 
mainland Portugal and to classify rhinitis in this age group. 
Output 3: To estimate the prevalence of physician-diagnosed asthma in the population aged 65 years 
or above living in mainland Portugal and to analyze its association with the presence and 
classification of rhinitis. 
Output 4: To identify and characterize “hypothesis-free” multidimensional early childhood wheezing 
phenotypes related to asthma persistence in adolescence. 
Output 5: To analyze the association between PNIF and (1) lower airway patency in children with 
allergic rhinitis and asthma and healthy children and (2) allergic rhinitis and asthma control 
subjective evaluation. 
Output 6: To uncover “hypothesis-free” salivary and urinary differentiating metabolic features in 
children with allergic rhinitis and asthma multimorbidity compared to healthy children. 
Output 7: To assess potential exogenous contaminants in EBC metabolic profiling. 
 












Chapter 3: Methods 
In order to address these aims, distinct methodologies were used: 
 Cross-sectional, population-based, nationwide surveys of citizens living in Portugal, using 
standardized procedures applied by telephone interview (Output 1) and face-to-face interview 
(Outputs 2 and 3). The questionnaires included information on asthma and rhinitis allowing 
the analysis of the association between these two conditions. 
In Output 1, data from all individuals aged below 18 years who participated in the INAsma 
study (representative sample of all aged citizens in Portugal) were analyzed. The inclusion of 
716 children allowed estimation of current asthma prevalence with an error of 2% (precision) 
and 95% confidence interval. 
In Outputs 2 and 3, the target population was the population aged 65 years or above living in 
mainland Portugal. The primary endpoint was rhinitis prevalence and a representative sample 
was analyzed, including a total of 3678 responders (Output 2). This sample allowed the 
estimation of asthma prevalence with an error <0.9% (precision) in 95% confidence interval 
(Output 3).  
 Prospective cohort study of children aged below 7 years with recurrent wheezing (Output 4). 
The cohort included 308 children that were systematically evaluated at three, eight and 13 
years of follow-up. Multivariable logistic regression models for persistent asthma in 
adolescence were developed based on questionnaires and skin prick tests data. Phenotypes 
were identified with k-means cluster analysis of variables selected with the logistic regression 
analysis and compared for predicting asthma prevalence, use of control treatments and lung 
function in childhood and adolescence. 
 Cross-sectional, case-control study of 65 school-aged children with allergic rhinitis and 
asthma and 24 healthy children (matched for age and gender), with laboratorial assessments. 
a) Respiratory functional laboratory: Sequential assessments of PNIF before and after 
nasal decongestion and spirometry with bronchodilation test were performed. The 
CARATkids was used for the subjective control assessment in children with allergic 
rhinitis and asthma. Associations were investigated by multiple linear regression 
models (Output 5).  
b) Analytical laboratory: Untargeted metabolomics analysis of urine and saliva samples 
collected from each child was performed using NMR spectroscopy. Spectroscopic 
and clinical data were subjected to statistical analysis including multivariable and 
univariable approaches (Output 6). 
Additionally, EBC was collected from seven volunteers, together with room air 
samples collection. All samples were analyzed using NMR spectroscopy and the 
resulting spectra were compared (Output 7). 
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Part 2: Definition of early childhood wheezing 
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Background: Exploratory molecular profiling of asthma phenotypes may contribute with novel 
insights to incorporate pathobiologic characteristics and biomarkers in the progression from clinical 
phenotypes to endotypes. This study aimed to uncover “hypothesis-free” salivary and urinary 
differentiating metabolic features in children with allergic rhinitis and asthma multimorbidity compared 
to healthy children. 
Methods: Cross-sectional exploratory study including 65 children (6-12 years) with allergic rhinitis and 
asthma and 24 healthy children, matched for age and gender. All children underwent saliva and urine 
collection, spirometry with bronchodilation test, exhaled nitric oxide (FeNO) measurement and skin 
prick tests. Untargeted metabolomics analysis of saliva and urine was performed using nuclear 
magnetic resonance (NMR) spectroscopy. Spectroscopic and clinical data were subjected to 
multivariable and univariable statistical analyses. 
Results: Principal component analysis showed no sample clustering according to allergic rhinitis and 
asthma in the salivary and urinary metabolic profiles. Univariable analysis followed by linear modelling 
revealed subsets of NMR spectral areas significantly different in the children with allergic rhinitis and 
asthma. Some metabolites contributing to these variables were identified: arginine, taurine, citrate and 
aspartate (in saliva), and quinolinate, butyrate, pantothenate, gluconate, pseudouridine and lysine (in 
urine). Quinolinate, butyrate and pantothenate levels correlated with spirometric parameters, while 
quinolinate, gluconate and pseudouridine correlated with FeNO levels. Urinary quinolinate and 
salivary citrate and aspartate levels were associated with multiple allergenic sensitization.  
Conclusion: The NMR-based exploratory metabolomics revealed differentiating subsets of spectral 
features in saliva and urine in children with allergic rhinitis and asthma multimorbidity, compared to 
healthy children. Some of these spectral areas were associated with lung function parameters, FeNO 
levels and multiple allergenic sensitization. Identified metabolites contributing to these areas included 
the previously reported asthma-related metabolites arginine, taurine, quinolinate and butyrate, and 
may support further studies regarding their role in allergic rhinitis and asthma multimorbidity-related 
metabolic pathways. 
 
Keywords: Allergy, Asthma, Children, Metabolomics, Multimorbidity, Nuclear Magnetic Resonance, 







Worldwide since early childhood, asthma affects the lives of several hundred million people. In spite 
of the advances in the last decades, this chronic disease remains associated with significant morbidity 
and high costs, mostly due to uncontrolled asthma
(1, 2)
. The complex heterogeneity and dynamics of 
the asthma syndrome is driving the search for distinct asthma clinical phenotypes, aiming further to 
look for asthma endotypes, i.e., “subtypes of asthma”, each being caused by distinct underlying 
pathophysiological mechanisms, with different treatment and prognosis, that would allow more 
targeted, effective (novel) therapeutic approaches
(3, 4)
. Presently, no widely agreed criteria upon 
asthma endotypes are described. Exploratory metabolic profiling of asthma can enable the detection 
of “hypothesis-free” biomarkers of the disease at the molecular level and provide novel insights on 
pathophysiologic mechanisms to the progression from clinical phenotypes to endotypes. 
Data from pulmonary tissue may hold the best chance of obtaining relevant data for specific asthma 
endotypes, given the direct airways evaluation. However, biomarkers need to be developed in 
accessible compartments that can be analyzed relatively easily and repeatedly. Urine is easily 
collected in most clinical scenarios and it is metabolically interesting as an end-product sampling of 
metabolic activity of a given organism
(5)
. Preliminary metabolomics data have shown that urine 
samples may be a surrogate of pathophysiologic processes that occur in asthma and suggested 
distinct metabolic features associated with this disease
(6-14)
. Recently, liquid chromatography 
combined with mass spectrometry was applied to a pilot study of saliva samples in asthmatics, also 
demonstrating the potential to discriminate asthma
(15)
. To date, untargeted metabolomics studies have 
reported a broad number of different metabolites associated with asthma
(16, 17)
. Some metabolites 
were identified as significant in at least two exploratory studies, including adenosine, arginine, 
phenylalanine, taurine, tyrosine, glucose, acetate, butyrate, propionate, formate, ethanol, methanol 
and urocanate
(8, 9, 18-25)
. One possible explanation for non-replicated results may be associated with 
the fact that most of the previous metabolomics studies focused on distinguishing asthma cases from 
healthy controls, with only a very few number of studies examining particular clinical asthma 
phenotypes
(16, 17)
. Exploring the metabolic profiling of clinically defined asthma phenotypes reduces 
heterogeneity and potential bias. The most prevalent and consensual phenotype in childhood is 
“allergic asthma”, typically accompanied by clinically relevant sensitization to allergens and 
association with other diseases, in particular allergic rhinitis
(4)
. The well-known link between allergic 
rhinitis and asthma has recently been supported by large-scale unbiased clustering at the population 
level, suggesting that undisclosed mechanisms underlying these diseases need to be investigated 
together, considering the childhood “allergic multimorbidity” cluster
(26, 27)
.  
In this study, we hypothesized that the metabolic activity of children with allergic rhinitis and asthma 
would differ from that of healthy children and that NMR could measure such differences in saliva and 
urine samples. Thus, we aimed to uncover “hypothesis-free” differences in salivary and urinary 






MATERIALS AND METHODS 
Study design and participants 
In total, 65 children (aged 6-12 years) with allergic rhinitis and asthma were recruited for a cross-
sectional study in the Allergy Center outpatient’s clinic at CUF Descobertas Hospital in Lisbon, from 
May until October 2015. 
Asthma was diagnosed according to the Global INitiative for Asthma (GINA) recommendations
(4)
, by a 
history of respiratory symptoms such as wheeze, breathlessness, chest tightness and cough that 
varied over time and in intensity, occurring for more than 12 months, together with variable expiratory 
airflow limitation, documented by positive bronchodilator reversibility testing. Rhinitis was defined as 
the presence of nasal itching/rhinorrhea/sneezing and/or nasal obstruction, occurring during at least 
two consecutive days for more than one hour on most days
(28, 29)
. Allergic rhinitis and asthma 
multimorbidity was considered in those children with self-reported symptoms of rhinitis and asthma 
upon aeroallergen(s) exposure, with positive skin prick test to the allergen(s). A convenience-driven 
sampling was used, stratified according to asthma control defined by current GINA 
recommendations
(4)
; children with controlled, partly controlled and uncontrolled asthma were recruited 
in an approximate 1:1:1 ratio. 
Children with any other diagnosed inflammatory (except atopic dermatitis
(30)
), respiratory or cardiac 
disease were excluded. These encompassed diagnosed congenital or perinatal diseases including 
cardiopulmonary diseases, pneumonia / pneumonitis, aspiration, cystic fibrosis, immunodeficiency or 
gastro-esophageal reflux disease. Children with asthma exacerbation, systemic corticosteroids use or 
respiratory infection within four weeks of the study visit were also excluded.  
Age and gender-matched healthy children were screened by no positive answers on the International 
Study of Asthma and Allergies in Childhood (ISAAC) questionnaire
(31)
, and no atopy assessed by skin 
prick tests. These children had no history of respiratory, inflammatory or other diseases likely to 
interfere with the study (such as those described above) and no acute disease within the previous 
four weeks or any drug intake within the previous eight days before the study visit. 
All diagnoses were validated by medical specialists, based on anamnesis, clinical files and medical 
examination (performed in all children). 
Informed consent was obtained from each child’s parents/legal guardians. This study was approved 
by the Ethics Committee of CUF Descobertas Hospital and of NOVA Medical School and by the 
Portuguese Data Protection Authority. 
 
Sample collection and Measurements 
Prior to the study visit, subjects had not taken inhaled corticosteroids, short-acting beta-agonists and 
anti-cholinergics for >12 hours; long-acting bronchodilators for >24 hours, leukotriene receptors 
antagonists for >36 hours, and anti-histamines for >7 days. All children were asked to refrain from any 
drink, food intake or tooth brushing at least one hour before samples collection. 
In the study visit, saliva and urine samples were consecutively collected, followed by exhaled nitric 
oxide (FeNO) measurement and, thereafter, lung function and skin prick tests. Each child performed 










1. Saliva and urine samples collection  
Saliva was collected by a passive drool technique into a sterile cup cooled on ice. Immediately after, 
midstream urine specimens were collected into sterile cups. All samples were immediately stored (-
80ºC) until analysis. 
 
2. NMR measurements 
All chemicals and consumables were purchased from Sigma-Aldrich
®
 (Germany) except for the NMR 
tubes and 96-well Ritter plates, which were purchased from Bruker
®
 (Bruker Biospin Ltd., USA). 
Frozen urine and saliva aliquots were thawed in a refrigerator overnight. Cellular components and 
other insoluble material were spun down by centrifugation for 10min at 3184×g and 4°C. The 
supernatants were transferred into the 96 Ritter plates. A volume of 0.225mL of each supernatant was 
mixed with 0.025mL of phosphate buffer (1.5M K2HPO4/KH2PO4, 2mM NaN3 in D2O, pH 7.4) 
containing 4mM of sodium 3-trimethylsilyl [2,2,3,3-D4] propionate as internal standard and chemical 
shift reference. A volume of 0.165mL of each sample-buffer mixture was transferred to 3mm 
SampleJet NMR tubes using a Gilson 215 robotic liquid handler and placed in refrigerated racks (6°C) 
of a SampleJet system (Bruke Biospin Ltd., USA) until the NMR measurements. 
NMR spectra were collected on a Bruker 14.1T AVANCE II spectrometer, equipped with a triple 
resonance inverse cryoprobe. For each sample a one-dimensional (1D) 
1
H NMR experiment was 
collected at 27˚C, using the noesygppr1d pulse program (Topspin 3.0, Bruker Biospin Ltd., USA)
(32)
. 
Excitation pulses were automatically calibrated for each sample, while the water signal was 
suppressed by presaturation. The recorded data was automatically processed (phase and baseline 
correction, line broadening by a factor of 1Hz and referencing to the chemical shift of 3-trimethylsilyl 
[2,2,3,3-D4] propionate at 0.0ppm). All NMR measurements were performed in a random order. 
Two dimensional (2D) 
1
H J-resolved (Jres) NMR spectra were also recorded for each sample to assist 




H) Correlation Spectroscopy and 




C Heteronuclear Single-Quantum Correlation 
experiments were acquired for a small set of pooled samples. These samples were made by mixing 
small aliquots from each of the samples of the study either for urine or saliva. The 2D data was 
exclusively used for the identification of the NMR peaks in combination with the proprietary database 
Biorefcode implemented in AMIX software (Bruker Biospin Ltd., USA).  
 
3. Fractional exhaled nitric oxide measurement 
The FeNO was measured with the NIOX Vero® system (Aerocrine, Sweden) using a single-breathing 




4. Lung function tests 
Spirometry with bronchodilation test (Jaeger MasterScreen™ system from Carefusion with a Flow 
Spirometer (Lilly Pneumotacograph) with Software version - JLAB 5.31.0.83) were performed and 
interpreted, according to international recommendations
(35)
. Global Lung Initiative normative data was 










5. Skin prick tests 
Skin prick tests were performed according to international recommendations
(36)
. The skin was pricked 
with steel lancets (Prick Lancetter®, Hollister-Stier Laboratories, USA), and the following allergen 
extracts were applied: Dermatophagoides pteronyssinus, Dermatophagoides farinae, Lepidoglyphus 
destructor, Parietaria, grass pollen mixture, olive tree pollen, Alternaria, dog and cat epithelium (Bial-
Aristegui®, Spain). Histamine hydrochloride (10 mg/ml) was used as a positive control; a saline 
solution was the negative control. A wheal mean diameter >3 mm was considered a positive test.  
Atopy was considered when at least one skin prick test was positive. Multiple sensitization was 
defined when skin prick tests were positive to two or more of the following aeroallergen groups: house 
dust mites, pollens, molds and pets. 
 
Statistical analysis 
1. Analysis of clinical and demographic data 
Continuous variables were expressed as the mean and standard deviation, or median and extreme 
values in case of no normal distribution. Comparisons were performed with parametric independent t-
test or one-way ANOVA or non-parametric Mann-Whitney or Kruskal-Wallis tests, followed by post-
hoc multiple comparisons according to Bonferroni test. Correlations were analyzed using Spearman’s 
rank coefficient. Categorical variables were expressed as absolute and relative frequencies. 
Comparisons were performed with the Pearson’s chi-square test. P-values <0.05 were considered 
significant. Data analyses were performed with SPSS® version 24.0 (IBM SPSS, Chicago, IL, USA).  
 
2. Analysis of spectroscopic data 
Pre-processing of NMR data prior to statistical analysis was performed with in house routines written 
in Matlab 2014a (The Mathworks, Inc., USA) and Python 2.7 (Python Software Foundation, 
www.python.org, USA). The region from 0.5 to 9.5ppm of all 1D NMR spectra was binned using the 
adaptive intelligent binning approach
(37)
, resulting in 381 variables (bins) for urine and 450 variables 
for saliva. Both datasets were normalized using the Probabilistic Quotient Normalization method to 
correct for dilution differences
(38)
. The final dataset consisted of 381 variables x 89 samples for urine 
and 450 variables x 88 samples for saliva (the spectrum from one sample did not meet the quality 
criteria for further analysis and was excluded). Finally, the normalized data was centered, scaled to 
unit variance and log transformed for the statistical analysis.  
The statistical analysis was performed in R statistical environment (http://www.r-project.org/, R 
versions 3.3.2, Austria). Two main statistical approaches were used. In the first approach, 
multivariable analysis was performed with Principal Component Analysis (PCA). In the second 
approach, Mann-Whitney U test was used for variable preselection with regard to the differences 
between children with allergic rhinitis and asthma (with partly controlled or uncontrolled asthma) and 
healthy children (significance was expressed at p<0.05). Further subset selection was performed by 
linear modelling. Stepwise linear regression was applied to select the final best set of variables 
(Figure 1). 
Identification of the metabolites contributing to the significant variables (odds-ratio ≠1) was performed 
by search of the Biorefcode (Bruker Biospin Ltd., USA) database and further verification of the 









Table 1 indicates the main characteristics of the study participants. All children were Caucasian. 
Fourteen children with allergic rhinitis and asthma also had concurrent atopic dermatitis (21.5%). No 
statistically significant differences were found regarding demographic and anthropometric parameters. 
Lower spirometric values and higher FeNO levels were found in children with allergic rhinitis and 
asthma, the worst values in uncontrolled asthma (Bonferroni post-hoc testing, p≤0.01).  
 
Principal component analysis of NMR spectroscopy datasets 
The PCA was applied to urine and saliva NMR datasets. The first two components of both urine and 
saliva PCAs explained less than 35% of variation of the data (Figure 2). In order to evaluate the 
influence of allergic rhinitis and asthma as well as asthma control in the metabolic profile, the PCA 
score plot was colored according to these groups, but neither contributed to the main sources of 
variation of the data in both urine and saliva models (Figure 2). 
Other potential factors that could have influenced the metabolic profile such as gender, age and body 
mass index were also investigated. None of them had any influence on the metabolic profile of either 
urine or saliva samples (Supplementary Figures S1, S2 and S3).  
 
Univariable analysis followed by linear modelling 
After Mann-Whitney U test, several variables were significantly different between healthy children and 
those with allergic rhinitis and asthma (Table 2). Subset selection by linear modelling reduced the 
number of variables; the best models chosen by logistic regression contained from five to eight 
variables (Table 2). Some metabolites contributing to these variables were identified (Table 3): 
arginine, taurine, citrate and aspartate (in saliva), and quinolinate, butyrate, pantothenate, gluconate, 
pseudouridine and lysine (in urine). Figures 3 and 4 show these differentiating variables levels in urine 
and saliva, respectively. 
 
Associations between asthma differentiating spectral variables and clinical parameters 
Variables including quinolinate, butyrate, pantothenate, and an unidentified metabolite correlated with 
spirometric parameters, while FeNO levels correlated with the variables comprised by quinolinate, 
gluconate and pseudouridine (Table 4). No correlations were found between salivary variables and 
spirometric parameters or FeNO.  
Urinary quinolinate levels were higher in children with FEV1 z-score<-1.64 (p=0.015), positive 
bronchodilation test (p=0.002) and multiple allergenic sensitization (p=0.037). Multiple sensitization 
was also associated with higher levels of the salivary variable comprising citrate and aspartate 
(p=0.036). 
Lower levels of the salivary variable comprising arginine and taurine were found in children treated 
with montelukast on the previous week (p=0.008). No other associations were found between any of 
the differentiating spectral areas and drugs intake on the previous week, namely inhaled or nasal 
corticosteroids, inhaled bronchodilators or montelukast. No association was found between any 








The exploratory metabolomics of urine and saliva resulted in differentiating subsets of NMR spectral 
features in children with allergic rhinitis and asthma, compared to healthy children. Moreover, some of 
these metabolic spectral areas were associated with lung function parameters, FeNO levels and 
multiple allergenic sensitization. Several metabolites contributing to some of these features were 
identified, stimulating further studies to validate the results and generating several hypotheses 
regarding their role in allergic rhinitis and asthma multimorbidity-related metabolic pathways to be 
further explored. 
At variance with most of the previous metabolic profiling studies, we used untargeted metabolomics to 
uncover “unbiased” differentiating metabolic features of a specific asthma phenotype and considered 
allergic rhinitis and asthma multimorbidity in children for the first time. Furthermore, we have used two 
non-invasive samples, collected consecutively from each child, aiming for a more “systemic view”, yet 
totally non-invasive. A balanced sample of patients comprising different asthma control levels was 
studied, together with age and gender-matched non-atopic healthy children. All diagnoses were 
validated by specialist medical doctors and all children were characterized regarding airway 
inflammation measured by FeNO and lung function with spirometry and bronchodilation test. Spectral 
NMR areas of urine and saliva were associated with allergic rhinitis and asthma multimorbidity using 
statistical analyses that involved a pre-selection of variables followed by linear modelling. Compound 
identification was performed to benefit possible methodology validation, as well as raising 
pathophysiological hypotheses. 
Molecular profiling by untargeted approaches may support the characterization of asthma phenotypes 
at the molecular level and contribute with new insights to the progress from clinical phenotypes to 
endotypes. Although diversity exists within the childhood “allergic asthma” phenotype
(39)
, focusing on 
a defined clinical phenotype reduces clinical heterogeneity and may be useful in the molecular 
characterization of asthma “subtypes”, allowing easier comparison of results by different research 
groups. In fact, one probable justification for the non-replicated results obtained by the existing 
metabolic profiling studies in asthma may rely on the distinct study populations, especially considering 
the heterogeneity of asthma
(4, 40)
. 
Multivariable analysis by PCA of NMR spectra of urine and saliva showed no samples clustering 
according to allergic rhinitis and asthma multimorbidity, or asthma control. Similar results have been 
previously described in asthma profiling studies by other research groups using different analytical 
methods and biospecimens including urine, saliva, plasma and exhaled breath condensate (EBC)
(6, 7, 
9, 10, 14, 15, 41, 42)
, and may be due to the fact that the metabolome is sensitive to both internal and 
external influences that may be unrelated to disease status. It could also reflect heterogeneity in 
allergic rhinitis and asthma-related metabolic pathways or even still limited analytical coverage or 
discriminatory capacity to identify global shifts in multiple correlated metabolites. Yet, this does not 
mean that there are no metabolic variables that are useful to differentiate asthma. Feature selection 
can allow for the extraction of relevant metabolites
(43)
. This is applied to: a) reduce overfitting, b) 
improve model performance and c) gain a better understanding of the relationship between the 
metabolic features and the response clinical variable. Several strategies have been used by different 
research groups to identify metabolic discriminatory features classifying asthmatics from healthy 
controls. We chose univariable spectral area selection to measure the importance of each variable 
individually on allergic rhinitis and asthma in a simple and easy to interpret approach
(41, 42, 44, 45)
. These 
preselected sets of variables were further reduced by linear modelling and logistic regression was 
applied to select the final best set of spectral areas. As response variable, comparisons were made 
between healthy children and children with partly controlled and uncontrolled asthma, since more 
significant differences were expected to be found than in controlled asthma. Since partly controlled 
and uncontrolled asthma may be metabolically heterogeneous themselves, separate models were 





were identified that differentiated the two groups, except for pantothenate which was identified in urine 
as a relevant differentiating metabolite in both models. Different from previous metabolic profiling 
studies in asthma, we analyzed saliva and urine simultaneously from the same subject, but found 
distinct differentiating metabolites subsets in the two samples. However, some of the identified 
metabolites were indeed common to previous metabolomics profiling studies results and have been 
linked to asthma. In particular, arginine and fatty acid metabolism were previously reported pathways 
in asthma metabolomics studies, regarding both experimental animal models of allergic airway 
inflammation
(46-49)
, and clinical studies in humans
(7, 19, 21, 22, 24, 25)
. 
An enrichment of pathways reflecting increased metabolism of amino acids in asthma has been 
anticipated
(16)
. Amino acids are mediators of immunological activities in asthma and may have 
antioxidant functions, namely taurine
(20, 24)
. Urinary citrate has been previously reported to reduce 
during asthma exacerbations
(11)
. Low arginine systemic levels have been described in asthmatics, 
which may be associated with induction of arginase activity by type 2 cytokines
(21, 50)
. Arginine also 
acts as a substrate for nitric oxide production
(51)
, but we found no association between salivary 
arginine and FeNO levels. Although we found that these amino acids distinguished allergic rhinitis and 
asthma cases, the link with the reduced level of free metabolites in the saliva and these diseases is 
unknown. This could be related to systemic levels but also to dietary changes or salivary gland 
secretion. Of relevance, taurine is the most abundant free amino acid, mainly in proinflammatory cells 
and tissues exposed to elevated levels of oxidants, such as the salivary gland, where it exerts a role 
in regulation of salivary flow. Altered salivary flow rates have been described in asthmatics, which can 
contribute to changes in saliva composition
(52, 53)
.  
Urinary quinolinate is an endogenous metabolite of tryptophan at the kynurenine pathway, which has 
been linked to inflammatory pathways
(54, 55)
. Its levels were found to be higher in serum and lower in 
EBC in adult patients with allergic asthma
(56)
. Moreover, systemic quinolinate has been associated 
with eosinophilic cation protein, eosinophils in bronchoalveolar lavage fluid and peak asthma 
symptom scores after rhinovirus challenge
(56)
. Interestingly, besides a negative correlation with lung 
function parameters, we also found a positive association between quinolinate levels and multiple 
allergenic sensitization and FeNO levels, which could further support quinolinate as a marker in the 
type 2 inflammatory pathway
(56)
. However, the pathophysiologic mechanisms of enhanced systemic 
quinolinate in asthma remain to be determined. Urinary tryptophan has been also identified as a 
discriminatory metabolite in asthmatic children
(7)
. The immunomodulatory function of indoleamine 2,3-
dioxygenase, the rate-limiting enzyme in tryptophan catabolism, and other compounds generated 
during tryptophan metabolism have also been described in asthma, supporting that further insights on 
this metabolic pathway may contribute to increased knowledge on    asthma
(20, 54, 56-58)
. 
Butyrate has also been identified in exploratory EBC metabolomics in asthma
(22, 25)
. This molecule is a 
short chain fatty acid, mostly produced in humans in the gut by anaerobic fermentation of undigested 
carbohydrates and fiber polysaccharides. Besides the role in the energy requirement, butyrate is 
suggested to be a mediator in the communication between commensal microbiota and the immune 
system, with multiple anti-inflammatory effects, including suppression of nuclear factor kappa B 
activation and interferon gamma production, upregulation of peroxisome proliferator-activated 
receptor gamma and promotion of peripheral regulatory T cell generation, affecting effector cells 
migration, adhesion, proliferation and apoptosis
(59-63)
. It has been recently reported that butyrate may 
influence innate lymphoid cells proliferation and function, associated with reduced airway hyperactivity 
and inflammation
(64)
. The principle mechanism of action involves epigenetic regulation through the 
inhibition of histone deacetylase
(59)
. Overall, histone deacetylase inhibitors have been considered in 
the treatment of asthma and other inflammatory lung diseases
(65)
. The lower levels of butyrate were 
associated with partly and uncontrolled asthma and impaired lung function. Taken together, these 
findings may bring additional evidence to the role of gut microbiome in allergic asthma
(66, 67)
. 
In our study, using the identified differentiating spectral region subsets, the obtained summary scores 
showed good classification accuracies. While metabolites associated with allergic rhinitis and asthma 




results require validation. This step is critical to assess true discriminatory ability and support for 
accuracy of the reported biomarkers in independent cohorts. Furthermore, essential steps in 
metabolomics studies design relate to monitoring external factors that may affect the metabolome and 
introduce significant bias to the results. External factors known to affect the metabolome include age, 
gender, body mass index and the circadian rhythm. Despite being well matched for age, gender, body 
mass index, and all samples being collected at the same time of the day, it is important to highlight 
that diet and current asthma treatment may have interfered with the urine and saliva metabolic profile 
in our study. Although care has been taken to refrain from drinking or food intake before samples 
collections and most medication was inhaled and had been stopped for at least 12 hours, we cannot 
firmly rule out that our results were not affected by diet or medication. Nevertheless, no association 
was found between any differentiating spectral area and self-reported specific food intake or fasting 
time or drug use on the previous week, except for oral montelukast which was associated to the 
variable comprising arginine and taurine in saliva. However, an explanation for this association is 
unknown to us, considering that montelukast had been taken more than 36 hours before saliva 
collection. Randomized trials and animal model studies analyzing the effect of medication on the 




In summary, this exploratory study supports the potential of untargeted metabolomics of non-invasive 
urine and saliva samples in the “unbiased” molecular characterization of childhood allergic rhinitis and 
asthma multimorbidity. We have identified a subset of the NMR spectral areas of urine and saliva 
significantly different in children with allergic rhinitis and asthma compared to healthy controls. Some 
of these metabolic variables were associated with such clinical readouts as lung function parameters, 
FeNO levels and multiple allergenic sensitization. Moreover, several metabolites contributing to the 
differentiating variables were identified, stimulating further studies to validate the results and 
generating hypotheses to be further explored, namely regarding the role of the previously reported 
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Table 1: Participants characteristics 
 
CHARACTERISTICS Healthy children 
(n=24) 










Age months, median (min-max) 116.0 (73.0-155.0) 105.0 (74.0-155.0) 115.0 (76.0-148.0) 128.0 (78.0-155.0) 0.106 
Gender male, n (%) 12 (50.0) 10 (50.0) 15 (71.4) 13 (54.2) 0.439 
BMI Kg/m
2
, median (min-max) 16.87 (12.85-22.20) 16.65 (13.66-23.40) 17.71 (13.31-22.79) 18.52 (14.18-24.61) 0.092 
Multiple sensitization, n (%) 0 (0) 11 (55.0) 13 (61.9) 15 (62.5) 0.860* 
Nasal topic corticosteroid use, n (%) 0 (0) 6 (30.0) 8 (38.1) 9 (37.5) 0.832* 
Inhaled corticosteroids use, n (%) 0 (0) 12 (60.0) 14 (66.7) 11 (45.8) 0.351* 
Inhaled LABA use, n (%) 0 (0) 6 (30.0) 4 (19.0) 10 (41.7) 0.259* 
Oral montelukast use, n (%) 0 (0) 0 (0) 3 (14.3) 4 (16.7) 0.201* 
Syst. corticosteroid < 6 months, n (%) 0 (0) 0 (0) 4 (19.0) 4 (16.7) 0.128* 
FEV
1
/VC z score, mean (SD) 0.79 (0.63) 0.21 (1.32) -0.83 (1.55) -2.63 (2.12) <0.001 
FEV
1
 z score, mean (SD) 0.85 (1.07) 1.26 (1.65) 0.19 (1.30) -0.88 (1.42) <0.001 
MMEF z score, mean (SD) -0.03 (0.90) -0.38 (1.39) -1.52 (1.50) -2.88 (1.44) <0.001 
Positive bronchodilation test, n (%) 1 (4.2) 0 (0) 6 (28.6) 18 (75.0) <0.001 
FeNO, median (min-max) 5 (0-24) 10 (0-87) 15 (0-94) 29 (7-104) <0.001 
BMI – body mass index; FeNO – fractional exhaled nitric oxide; FEV
1
 – forced expiratory volume in one second; LABA – long acting beta 2 agonist; 
min-max – minimum-maximum; MMEF – maximum midexpiratory flow; SD – standard deviation; Syst. – systemic; VC – vital capacity. 








Table 2: Variables preselection and characteristics of multivariable models for differentiating subsets of spectral variables classifying children with allergic 






Mann-Whitney U test Logistic regression final model 




 AIC AUROC 
Healthy vs Uncontrolled asthma Urine 29 8 54.23 0.903 30.31 0.988 
Healthy vs Partly controlled asthma Urine 19 5 48.07 0.877 26.11 0.978 
Healthy vs Uncontrolled asthma Saliva  43 5 41.71 0.785 35.42 0.955 
Healthy vs Partly controlled asthma Saliva 15 6 31.14 0.677 43.77 0.921 
AIC – akaike information criterion; AUROC – area under the receiver operating curve; LRch
2
 – likelihood ratio qui-squared 
 
 
Table 3: Identified allergic rhinitis and asthma differentiating metabolic variables 
 
Groups Sample Metabolites Odds-Ratio (2.5%-97.5% confidence interval) 
 
Healthy vs Uncontrolled asthma 
 
Urine 
Quinolinate 2.69 (1.10-8.90) 
Butyrate + Pantothenate 0.41 (0.16-0.87) 
Gluconate + Pseudouridine 2.30 (1.10-5.69) 
Healthy vs Partly controlled asthma Urine Pantothenate 0.19 (0.05-0.48) 
Lysine 9.90 (1.80-79.90) 
Healthy vs Uncontrolled asthma Saliva  Citrate + Aspartate 0.41 (0.17-0.81) 
Healthy vs Partly controlled asthma Saliva Arginine + Taurine 0.51 (0.23-0.98) 
 

















change in FEV1 (L) 
Bronchodilator 
change in FEV1 (%) 
Quinolinate 0.240 (0.024) -0.314 (0.003) -0.157 (0.141) -0.282 (0.007) 0.306 (0.004) 0.366 (<0.001) 
Gluconate+Pseudouridine 0.230 (0.030) -0.163 (0.128) -0.056 (0.604) -0.133 (0.213) 0.163 (0.126) 0.179 (0.093) 
Butyrate + Pantothenate -0.178 (0.227) 0.277 (0.032) 0.142 (0.183) 0.209 (0.050) -0.263 (0.013) -0.227 (0.032) 
X0.8402 (unknown) -0.162 (0.128) 0.227 (0.033) 0.040 (0.711) 0.222 (0.036) -0.228 (0.032) -0.216 (0.042) 
FeNO – fractional exhaled nitric oxide; FEV
1
 – forced expiratory volume in one second; MMEF – maximum midexpiratory flow; VC – vital capacity 




































Figure 1 – Data analysis workflow (* ARA: allergic rhinitis and asthma, considering uncontrolled 
asthma or partly controlled asthma). 
  
Urine dataset, n=381 
Saliva dataset, n=450 
Univariable bin selection with 
Mann-Whitney U test 
Statistically significant bins 
healthy vs. ARA* 
Subset selection  
with linear model 
Final model with the best set of bins 
healthy vs. ARA* 
Model performance and final subset selection  
with stepwise logistic regression 
Model with the best subset of 10, 7 or 5 bins 
healthy vs. ARA* 








Figure 2 – Principal component analysis score plots of urine (A) and saliva (B) samples. Samples are 
colored according to disease status and asthma control. The first two components of the models 
explained 17% and 33% of the variation of the urine and saliva data, respectively. 





























Figure 3 – Boxplots of identified metabolites in urine to discriminate healthy children from children with allergic rhinitis and asthma, stratified according to 
asthma control: (A) pantothenate; (B) lysine; (C) quinolinate; (D) butyrate + pantothenate; (E) gluconate + pseudouridine; (n=89, * p<0.027).   
(A) (B) 
















































Figure 4 – Boxplots of identified metabolites in saliva to discriminate healthy children from children with allergic rhinitis and asthma, stratified according to 































Figure S1 – Principal component analysis score plot of urine (A) and saliva (B) samples, colored 
















Figure S2 – Principal component analysis score plot of urine (A) and saliva (B) samples, colored 
























Figure S3 – Principal component analysis score plot of urine (A) and saliva (B) samples, colored 
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The recently updated European Respiratory Society technical standards on exhaled biomarkers provide 
methodological recommendations of utmost importance for comparable results and potential use of 
exhaled biomarkers in clinical practice and research
(1)
. Exhaled breath condensate (EBC) composition 
can be influenced by several factors that arise during sample collection, storage and processing. One of 
these factors is the inhaled air composition
(1)
. Yet, ambient air controls have not been routinely reported in 
EBC studies. Addressing potential exogenous compounds in EBC becomes even more important with the 
growing number of “omics” studies using untargeted approaches with such multivariable analytical 
techniques as nuclear magnetic resonance (NMR) and mass spectrometry. In a seminal paper on NMR 
profiling of EBC, Bertini et al used a homemade EBC collecting device
(2)
. Humidified room air was pulled 
into the condensing apparatus and the analysis of this sample resulted in NMR spectra free of ambient air 
or device contamination signals
(2)




Izquierdo-García et al have reported the presence of a number of exogenous compounds in the room air 
samples, including, among other components, acetate, formate, propionate, lactate, benzoate, glycerol 
and propylene glycol
(3)
. Moreover, ambient air NMR profiles from the same collection room varied 
depending on the time of day or day of collection
(3)
.  
In our study, we used the disposable RTube
TM
 collection system (Respiratory Research, Inc.; Virginia, 
USA), cooled to -20ºC. EBC samples were collected on two different days from seven volunteers (two 
children and five adults; three with asthma). During collection, subjects breathed at normal frequency and 
tidal volume for 10 minutes, wearing a nose clip and were asked periodically to swallow saliva. In total, 
four room air samples were collected simultaneously with the EBC samples in two ways: (a) two samples 
using a calibrated syringe connected to the RTube mouthpiece, pumping 500ml of room air into the 
collection system at a flow rate of approximately 8L/min for 10 minutes, reproducing normal human 
breathing; (b) two samples using a vacuum pump connected to the outlet of the collection system for 10 
minutes, thus avoiding possible contaminations from the syringe material. All sampling procedures were 
carried out during the morning, in the same room (volume: 36m
3
; with air conditioning set to 24ºC). 
Collected samples were immediately stored in sterile high-grade polypropylene cryovials at -80ºC until 
their analysis by NMR. On the day of analysis, samples were thawed at room temperature and insoluble 
material was spun down by centrifugation. The supernatants were mixed with phosphate buffer (pH = 7.4) 
in deuterated water, in a 9:1 ratio of sample/buffer, and 
1
H NMR spectra were recorded in a 14.1 T NMR 
spectrometer (Bruker, Avance II); the NMR method was optimized according to Bertini et al.
(2)
. Figure 1 
shows the representative 
1
H-NMR spectra of the room air samples collected using the vacuum pump or 
the syringe (both spectra were identical) and the EBC sample. The composition of the room air spectrum 
was similar to the one from EBC, indicating a possible contamination from each sample to the other. 
Several reasons could be considered to explain these results, from environmental contamination to the 
effects of the condensing equipment and samples storage or processing methodology. Although the 
influence of each of these factors has not been analyzed individually, our spectra were similar to Bertini et 
al published EBC spectra, using similar analytic procedures
(2)
. Furthermore, the RTube
®
 collection system 
is made of inert materials and the NMR spectra of water from this collecting system has been shown to be 
clearly different from EBC spectra
(4)
. These strengthened a possible contamination of room air and EBC 
samples in our study. A number of possible factors could have contributed to the potential environmental 
contamination, including the limited space in the collection room, insufficient room ventilation and the 
exhaled breath of the assisting personnel. Subtracting the air background from the breath signal wasn’t 
feasible. This method is increasingly used in mass spectrometry breath analysis by measuring the relative 
abundance of the metabolites in exhaled breath and in ambient air, but such approach may not be easily 
translated to NMR-based metabolomics data. A solution implemented in the previous reports was the use 
of suitable filters
(1)
. Izquierdo-García et al placed a trap for air contained water-soluble organic 
compounds in the EBC collecting system, which removed most of the NMR spectral air signals
(3)
. A 









 condensers and obtained no NMR signals in the condensed 
room air
(5,6)
. Thus, pumping filtered air into the collector using high efficiency filters (against particles with 
approximately 0.3µm mass median aerodynamic diameter) gave clean reference spectra, independent of 
the sampling device. However, this provides no insight into the composition of the air inhaled by a patient. 
Another possibility would be the use of a standard air source during EBC collection. Although variable 
interaction between this source of air and EBC is inevitable, at least this procedure would better allow 
independence from room air variability.  
Our results reinforce the need to address potential exogenous components in EBC profiling studies. This 
can be particularly difficult in NMR-based metabolomics studies. Inhaled air sample controls collected 
simultaneously with EBC samples are essential as well as methodologic procedures that allow 






[1] Horvath I, Barnes PJ, Loukides S, et al. A European Respiratory Society technical standard: exhaled biomarkers in lung 
disease. Eur Respir J. 2017; 49: pii: 1600965. 
[2] Bertini I, Luchinat C, Miniati M, et al. Phenotyping COPD by 1H NMR metabolomics of exhaled breath condensate. 
Metabolomics. 2014; 10:302–11. 
[3] Izquierdo-Garcia JL, Peces-Barba G, Ruiz-Cabello J. Influence of ambient air on NMR-based metabolomics of exhaled 
breath condensates. Eur Respir J. 2012; 40:1294-6. 
[4] Sinha A, Krishnan V, Sethi T, et al. Metabolomic signatures in nuclear magnetic resonance spectra of exhaled breath 
condensate identify asthma. Eur Respir J. 2012; 39:500-2. 
[5] Motta A, Paris D, D'Amato M, et al. NMR metabolomic analysis of exhaled breath condensate of asthmatic patients at two 
different temperatures. J Proteome Res. 2014; 13:6107-20. 
[6] Maniscalco M, Paris D, Melck DJ, et al. Coexistence of obesity and asthma determines a distinct respiratory metabolic 












Figure 1 – Region of 
1
H 1D nuclear magnetic resonance spectra from ambient room air (up) and exhaled 











Chapter 5: Discussion 
A high prevalence of asthma was found in children (prevalence of current asthma 8.4%) and in the elderly 
(prevalence of physician-diagnosed asthma 10.9%) in the Portuguese population. For the first time, 
nationwide prevalence of rhinitis was estimated in the elderly and a high frequency was found (29.8%). 
Strong associations between rhinitis and asthma were described at the population-level in these two age 
groups. Despite being common diseases, these studies suggested that rhinitis and asthma care had been 
substandard, highlighting the need for a clinical integrated, global assessment of asthma and rhinitis 
multimorbidity also in children and the elderly. 
Atopy and rhinitis at preschool ages were independent risk factors for asthma persistence in 
adolescence, based on “unbiased”, multidimensional modelling of data from a cohort of children with 
preschool recurrent wheezing. Multimorbidity, particularly rhinitis with or without associated atopy, tended 
to predict a worse prognosis of symptoms persistence and impaired lung function in later childhood and 
adolescence, suggesting the demand for distinct management approaches. These studies further 
suggested the need for an integrated care pathway of asthma and rhinitis together, since the very 
beginning of symptoms. 
The consistent and independent correlation found between PNIF and lower airway patency (PEF and 
FEV1) in school-aged children may reflect the physiologic background for the common rhinitis and asthma 
multimorbidity. These independent correlations also suggested that, ideally, at least PEF values should 
be considered, besides age and gender, when evaluating nasal obstruction by means of PNIF in this age 
group. The objective evaluation of nasal function by PNIF provided complementary objective information 
to subjective control assessment in children with allergic rhinitis and asthma, in an integrated care 
pathway approach.  
Ultimately, the application of exploratory metabolomics approaches to uncover “unbiased” differentiating 
metabolic features in non-invasively collected samples of urine and saliva in children with allergic rhinitis 
and asthma was demonstrated to be feasible. Differentiating NMR spectral areas were suggested to be 
associated with the allergic respiratory multimorbidity in children. Some of these metabolic variables were 
associated with lung function parameters, FeNO levels and multiple allergenic sensitization. Moreover, 
several metabolites contributing to the differentiating variables were identified, stimulating further studies 
to validate the results and generating hypotheses to be further explored, namely regarding the role of the 
previously reported asthma-related metabolites arginine, taurine, quinolinate and butyrate in allergic 
rhinitis and asthma multimorbidity. The EBC metabolic profile was found to be highly comparable to 
ambient air spectral composition, reinforcing the importance of room ambient air control during samples 







Asthma prevalence and its association with rhinitis in the extremes of life 
The estimated prevalence of current asthma in children was 8.4% (95%CI 6.6%-10.7%), using the 
pediatric-specific data from the population-based, all-age, nationwide telephone interview INAsma study. 
The prevalence of rhinitis and of physician-diagnosed asthma were estimated to be 29.8% (95%CI 
28.4%-31.3%) and 10.9% (95%CI 9.9%-11.9%), respectively, in the epidemiologic, nationwide, face-to-
face interview elderly-targeted study. A strong association between asthma and rhinitis was found both in 
children and in the elderly. 
These studies were the first population-based epidemiologic studies aimed to estimate the asthma and 
asthma-like symptoms prevalence in Portugal among all pediatric ages (<18 years) and to estimate the 
prevalence of rhinitis and physician-diagnosed asthma in the elderly (>65 years), respectively. 
Representative samples of the Portuguese population were included. These two extremes of life were 
particularly vulnerable, internationally data lacking groups. Few nationwide studies on the prevalence of 
asthma across the entire pediatric population had been performed
(55, 56)
, and no previous study had 
reported the prevalence of asthma-like symptoms across all pediatric ages. On the other hand, 
nationwide epidemiologic data on rhinitis in the elderly did not exist at the international level. Our study 
was the first epidemiologic study exclusively dedicated to the elderly that concurrently evaluated rhinitis 
and asthma symptoms, reporting an association according to ARIA classification of rhinitis severity and 
duration. 
Both studies contributed to assess nationwide diseases prevalence in these population groups. However, 
several limitations need to be considered: 
a) Primary endpoint: In the pediatric study, the survey was not designed for children but rather for 
the overall Portuguese population. Although the questions included in the survey and the 
definitions used were similar to other previous pediatric studies
(130, 131)
, the sample size was 
calculated for the total Portuguese population and not for the pediatric population. In this study, 
the inclusion of 716 children allowed to estimate current asthma prevalence with an error of 2% 
(precision) in 95% confidence interval. 
The elderly-targeted study was designed to estimate rhinitis prevalence. The frequency of 
physician-diagnosed asthma was a secondary endpoint and data on lower airway symptoms was 
not collected. Yet, the inclusion of 3678 subjects allowed the estimation of physician-diagnosed 
asthma prevalence with an error of 0.9% (precision) in 95% confidence interval. 
b) Sampling methodology: In both studies, the use of the 2001 National Census for sampling could 
not account for the reduction in the number of births or the increase in the elderly population that 
occurred in the next decade; however, it was the most recently available data at the time of data 
collection. Nevertheless, the sampling strategies allowed that the number of each gender, age 




c) Diagnoses confirmation: Both studies were limited by the absence of physician evaluation and of 
objective biomarkers of lung function and atopy. Therefore, participants’ misclassification can be 
expected, as in any similar epidemiologic surveys and classification of allergic/non-allergic 
diseases is impaired. 
d) Questionnaire application: Other factors, such as recall or information biases may have also 
influenced the results. Nevertheless, the use of short and simple questionnaires, applied by 
trained interviewers, facilitated the inclusion of participants. It also minimized difficulties in reading 
or comprehending and the loss of compliance throughout the interview to reduce missing data. 





aged <15 years and by the adolescent when the participant was ≥15 years. This may limit 
comparisons between these age groups. Changes of parent-reported to auto-reported outcomes 
are debatable but recommended between school-age and adolescence
(133)
.  
Epidemiologic studies at the population level are important to increase knowledge on a disease or 
condition and to better define adequate health policies. However, prevalence estimates are highly 
dependent on the used definitions of a disease. Standardized operational definitions of asthma and 
rhinitis are lacking, which may lead to different estimates and preclude study results comparisons. In our 
study in children, a GA
2
LEN-adapted questionnaire was used, including the ECHRS questions on asthma 
symptoms
(46, 49)
. Current asthma was defined as lifetime asthma (i.e., a positive answer to “Has the child 
ever had asthma?”) plus at least one of three associated symptoms or medication use: “wheezing”, 
“waking with breathlessness” or “having an asthma attack” in the previous 12 months, or “currently taking 
asthma medication”. However, asthma prevalence varied according to different used definitions, from 
6.3% (lifetime asthma plus wheezing in the last 12 months) to 9.1% (lifetime asthma plus any asthma-like 
symptom in the last 12 months or current asthma medication). This highlights the impact of the asthma 
definitions used on its prevalence estimates
(134, 135)
. Wheezing is many times used as a proxy of asthma 
but it can be caused by many conditions other than asthma. Using wheezing alone as a proxy of asthma 
diagnosis can overestimate asthma prevalence, particularly in children aged <3 years
(136)
. Wheezing-
based asthma definitions are also limited by differences in the concept and perception of wheezing, with 
different meanings among parents and health professionals
(137)
. A more global description of asthma 
symptoms may be necessary to reduce the risk of misclassification of asthma. Thus, we have used 
composite measures and reported the different operational estimates, to allow for more accurate 




Our estimate of lifetime asthma in children was 11.2% (95%CI 9.1%-13.7%). It was based on the same 
question of the ISAAC study. The estimate in school-aged children was higher than that in the 6 to 7-
years-old age group in the Portuguese ISAAC survey (12.3% versus 9.8%), while our estimate for the 
adolescents was similar to that in the 13 to 14-years-old age group in the ISAAC survey (13.9% versus 
13.8%)
(50)
. In a cross-sectional, questionnaire-based (ISAAC-adapted) large survey including 5003 
children aged between 3 to 5 years living in mainland Portugal (ARPAkids study, performed in 2007), the 
prevalence of physician diagnosed asthma was 4.6% (95% CI 4.0%-5.2%)
(61)
. Another study performed in 
2010 reported similar estimates of physician diagnosed asthma (4.6%, 95%CI 3.9%-5.4%) in 3186 
preschool children attending day care centers in Lisbon and Porto
(138)
. Although the operational definitions 
of asthma were not the same, these estimates are not much distant from our results reporting current 
asthma in preschool children (6.5%, 95%CI 3.5%-11.6%). 
The prevalence of asthma has been shown to vary in the different countries. The prevalence of doctor 
diagnosis of lifetime asthma in the German pediatric population was 4.7% (using data from 2003-
2006)
(55)
. This prevalence is much lower than ours but it is in agreement with the estimated prevalence of 
lifetime asthma among German children reported in the ISAAC study (4.3% in 6-7 years-old and 7.5% in 
13-14 years-old children in Germany, versus 9.8% and 13.8% in Portugal, respectively)
(139)
. Data from the 
2010 National Health Survey for children aged <18 years in the United States of America reported an 
estimated doctor diagnosed lifetime asthma prevalence of 13.6% and current asthma of 9.5%
(56)
, which 
are similar to our estimations. 
In the elderly-targeted study, we could not present the more accurate composite measures of asthma. 
The lack of information regarding lower airways symptoms precluded these definitions. Therefore, current 




asthma on current treatment (estimated prevalence 7.6%, 95%CI 6.7%-8.4%) may be a proxy of the 
current asthma definition used in the pediatric study and thus suggest similar frequencies of the disease 
in the pediatric and in the elderly Portuguese population. Furthermore, the estimated prevalence of 
physician-diagnosed asthma on current treatment did not differ significantly from the estimated 
prevalence of current asthma in the INAsma subgroup analysis of subjects aged >65 years (8.0%, 95%CI 
6.7%-9.5%)
(53)
, suggesting that this might be a reliable approximation of the real prevalence in the 
Portuguese population. However, such direct comparisons may not be accurate, given the different 
criteria used for the definitions of asthma. In the INAsma study, the subgroup analysis by age groups 
considering children (aged <18 years), adults (18-65 years) and the elderly (>65 years) showed no 
statistically significant difference in the prevalence of current asthma in Portugal
(53)
. 
Adjusting for possible confounding factors, the prevalence of asthma in the INAsma study was lower in 
elderly subjects who reported no heart disease
(53)
. Since heart disease is common in the elderly and may 
be a cause of respiratory symptoms, the authors pointed out the possibility of an overestimation of current 
asthma in elderly subjects with cardiac disease. Asthma prevalence estimates did not change after 
adjusting for chronic bronchitis
(53)
. In the present study, in spite of the limitations due to physician-
diagnosed asthma being only self-reported and the lack of information on environmental exposures 
including tobacco smoke, the fact that a doctor’s diagnosis and current asthma treatment were 
considered could have helped to reduce bias and confounding factors related to respiratory symptoms 
caused by other conditions, such as heart disease, bronchitis or chronic obstructive pulmonary disease 
(COPD). Nonetheless, distinguishing asthma from COPD can be particularly difficult. COPD is often 
assumed to be an “aging-related disease”, leading physicians to diagnose COPD rather than asthma in 
the elderly
(140-142)
. Conversely, other studies report asthma overdiagnosis in adults, including COPD 
misdiagnosis with asthma
(143-145)
. Phenotypic overlap between these two main chronic obstructive 
diseases justified the recent adopted nomenclature of asthma-COPD overlap (ACO)
(6, 146)
.  
In multivariable analysis, asthma prevalence was similar in both genders and according to municipality 
typology, in accordance with the INAsma study
(53)
. Unlike suggested by other studies
(141, 147)
, the 
prevalence of asthma in the elderly did not diminish with age. However, we cannot exclude that our 
results may be influenced by an increasing tendency for asthma misclassification with COPD or other 
mimicking conditions, with increasing age
(143-145)
, which should be explored. 
In other epidemiological studies targeting elderly subjects from other countries, the prevalence of asthma 
varied between 3.6% and 7.6%
(147-157)
. However, the different selection criteria and definitions of asthma 
limit inter-studies comparisons. Asthma overdiagnosis or the other stated biases may have concurred for 
the higher prevalence obtained in this study. The clinical validation of the epidemiologic definition of 
asthma in this age group is also needed. A study including medical evaluation, information on tobacco 
and other environmental exposures, and lung function parameters would be of utmost importance to 
address this issue in the elderly. 
Regarding rhinitis, population-based studies in the elderly are very scarce. Only one study performed in 
Mexico City had previously shown that allergic rhinitis was present in 3.6% of 333 elderly subjects who 
were attending a social security recreation center
(149)
. In a more recent community-based elderly 
population cohort study in Korea including 982 elderly adults, the prevalence of current rhinitis was 
25.6%
(158)
. In all-ages epidemiologic studies, subgroup analysis reported rhinitis prevalence between 
13.0% and 25.9% in the elderly
(86, 148, 159-161)
. However, similarly to epidemiologic asthma studies, different 
selection criteria and rhinitis definitions restrict inter-study comparisons. Our present findings are in 
agreement with the previous study reporting rhinitis prevalence in adults in Portugal
(86)
. That study, 
performed in 2004, using questions and a rhinitis definition that were similar to those used in the present 







subpopulation analysis found that rhinitis prevalence in subjects aged above 65 years was 25.9%. The 
higher prevalence observed in the present study (29.8%) may reflect either a more accurate estimation of 
rhinitis in the elderly or an actual increasing tendency in rhinitis prevalence in this age group over the 
years. In the INAsma study, 22.1% of included subjects had rhinitis (the same percentage as found in 
children)
(53)
, but direct comparisons are limited because, again, different sampling and definitions for 
rhinitis were used. “Allergic rhinitis” was defined in the INAsma study as a positive answer to the question: 
“Do you have any nasal allergies, including hay fever?”. This is clearly different from the composite 
definition used in the study in the elderly group (i.e., presence, usually or in the last 12 months, of at least 
two of the following symptoms: “repeated sneezing and itchy nose”, “blocked nose for more than one 
whole hour”, or “runny nose when not having a cold or flu”), based on ECRHS and ARIA
(23, 162)
. This 
definition, requiring the presence of at least two nasal symptoms, can suggest the diagnosis of allergic 
rhinitis together with the fact that 68.6% of the elderly had concomitant complaints of red eye, eye pruritus 
and epiphora, suggesting allergic rhinoconjunctivitis. However, the definitions of allergic rhinitis and 
allergic rhinoconjunctivitis were not used because they require the assessment of the specific 
immunological mechanisms involved and that was not part of this study. Other rhinitis subtypes could not 
be excluded. Still, this definition of rhinitis was important to rule out some of other causes of nasal 
symptoms, namely the so-called rhinitis of the elderly or senile rhinitis when characterized by clear 
rhinorrhea without other nasal symptoms
(23, 26)
. We also found a higher prevalence of rhinoconjunctivitis 
than that previously reported in adults (18.4%)
(86)
. A study comparing the characteristics of allergic rhinitis 
in younger and older patients suggested that elderly patients have rhinitis plus conjunctivitis more 
frequently than young adults
(163)
.  
The link between asthma and rhinitis was relevant in the children and in the elderly. Our data contributed 
to support this association at the population level in pediatric and older ages. The presence of rhinitis in 
children was associated with a higher prevalence of having any asthma-like symptom (OR 3.67, 95%CI 
2.52-5.39). A strong association was found between current asthma and rhinitis in children (OR 5.20, 
95%CI 3.05-8.85). On the other hand, about 80% of the elderly subjects diagnosed with asthma had 
rhinitis; among elderly subjects with rhinitis, 30% reported asthma diagnosed by a doctor. The prevalence 
of asthma diagnosis increased with the number of nasal symptoms, especially when they were 
associated with ocular symptoms, from 2.1% without rhinitis symptoms to 39.3% with three nasal 
complaints and 44.4% if nasal symptoms were accompanied with ocular symptoms. The fact that the 
association between rhinitis and asthma has been particularly notable in elderly patients with 
rhinoconjunctivitis may suggest an increased risk of asthma when there is greater likelihood of 
involvement of allergic mechanisms. Rhinoconjunctivitis was more frequent in elderly subjects with 
physician-diagnosed asthma with current treatment, compared to those without asthma treatment. Yet, as 
mentioned before, to confirm this hypothesis, objective biomarkers of specific immunologic mechanisms 
would be needed, which we did not perform. The ARIA classification of rhinitis provided important 
information with regard to the strength of the association with asthma, as it increased with increased 
persistency and severity of rhinitis, from mild intermittent rhinitis (OR 8.3, 95%CI 6.1-11.4) to moderate-
severe persistent rhinitis (OR 39.9, 95%CI 27.5-58.0). While contradicting some previous studies
(164-166)
, 
moderate-severe persistent rhinitis had an especially strong association with asthma, as also reported by 
other authors, in different age groups
(23, 167-171)
. Together, these results supported the extensive nose-lung 
interaction also in children and in the elderly. 
 
Characterization of asthma-like symptoms in children in Portugal  
The prevalence of asthma-like symptoms in children was 39.4% (95%CI 35.7%-43.3%). “Waking during 




wheezing (i.e., “wheezing in the last 12 months”), with an estimated prevalence of 19.1% (95%CI 16.4%-
22.1%). Wheezing prevalence was highest in children aged <6 years (31.0%, 95% CI 24.4-38.5) and 
significantly decreased with age. After the age of 5 years, most children with wheezing exhibited 
“wheezing without a cold” and “wheezing with breathlessness”. Although no differences were found in the 
prevalence of current asthma in both genders, wheezing was more common in males (OR 1.96, 95%CI 
1.30-2.97). These results suggested that age influenced asthma-like symptom patterns and were in 
agreement with other studies suggesting that wheezing in younger children was more closely related to 
immature airways and reduced airway caliber (particularly in young boys) and viral respiratory 
illnesses
(172)
, whereas older children with wheezing tended to be symptomatic without concurrent 
respiratory infections. 
In the ARPAkids study, the prevalence of current wheezing in children aged 3 to 5 years was 24.5% 
(95%CI 23.3%-25.7%), which was similar to our results. A multinational study of children aged 1 to 5 
years living in Europe and in the United States of America showed that approximately one-third had 
wheezing, coughing or breathlessness
(130)
, which was lower than our observation in children aged <6 
years (47.9%). However, the time period considered in that study was only 6 months, while the time 
period in our study was 12 months. A study investigating the prevalence of asthma-like symptoms in New 
Orleans inner-city children aged 5 to 18 years found that 27.3% reported “cough at night, apart from colds 
or chest infections”
(173)
. Although no distinction was made regarding different causes of cough and 
associations to respiratory infections, the frequency of waking with cough in our study was rather similar 
(30.9%). 
Thus, the prevalence of asthma-like symptoms in children was high, especially in younger ages. No 
statistically significant differences were found in the prevalence of asthma-like symptoms or current 
asthma according to region or any other analyzed socio-demographic variables. 
Among children with current asthma, the majority had “wheezing” (76.5%, 95%CI 65.4%-84.9%) or 
“waking during the night with cough” (68.7%, 95%CI 56.6%-78.7%). These were the two most common 
reported symptoms, suggesting uncontrolled disease. 
 
Characterization of rhinitis in the elderly population in Portugal  
The most common nasal symptom in elders with current rhinitis was “runny nose without a cold” followed 
by “sneezing and itchy nose”. The latest was the most reported symptom in the rhinitis study in adults
(86)
. 
Differences in nasal symptoms in the elderly may be expected, possibly due to concomitant age-related 
changes in nasal physiology in the elderly (nasal glandular atrophy, vascular changes with reduced nasal 
blood flow, decreased nasal humidification, decreased mucociliary clearance, and structural changes of 
the nose, including collagen atrophy and weakening of the septal cartilage)
(174-177)
, which may contribute 
to more frequent watery rhinorrhea. A neurogenic dysregulation may be considered when topical 
ipratropium bromide is effective in reducing rhinorrhea in these patients
(26)
. In fact, it is likely that several 
mechanisms underlie the pathogenesis of rhinitis in the elderly, with potential interaction between 
inflammatory conditions and the influence of aging on nasal physiology
(26, 178)
. 
For the first time, rhinitis was classified according to ARIA in the elderly at the population level. We found 
that 49.1% of the elders had mild intermittent rhinitis, 7.0% mild persistent rhinitis, 27.5% moderate-
severe intermittent rhinitis, and 16.4% moderate-severe persistent rhinitis. Rhinitis symptoms can become 
milder with age
(178, 179)
. However, in our study, more than 40% of the elders with rhinitis presented 





population. The overall rhinitis symptoms duration was of more than 25 years in the majority of the elders, 
showing a long-term disease. 
Current rhinitis prevalence was higher than the national prevalence in Alentejo (57.7%) and Lisbon and 
Tagus Valley (35.7%), but both regions presented higher prevalence of intermittent rhinitis. Overall rhinitis 
symptoms and current rhinitis prevalence did not differ between elders living in rural or urban regions. 
However, those living in a rural region had a higher prevalence of moderate-severe persistent rhinitis. 
This was an unexpected result. Several studies have found that the prevalence of allergic rhinitis was 
higher in urban than in rural areas
(180-182)
. Moreover, in the previous study in adults
(86)
, rural inhabitants 
presented significantly higher levels of intermittent rhinitis. It is possible that confounding factors, such as 
lifetime changes in the living region (from urban to rural regions and vice versa), may have contributed to 
these results, though the influence of other environmental factors could not be excluded. 
 
Asthma and rhinitis in the extremes of life: substandard care? 
Less than half of children with current asthma had been on inhaled controller medication in the previous 
12 months, despite being symptomatic. Those who only used inhaled reliever medications were twice as 
likely to have experienced an “asthma attack” in the same time period. Despite the recommendation to 
perform lung function tests for the diagnosis and follow-up of asthma patients, only 52.9% of those aged 
≥6 years had ever undergone lung function tests. Taken together, our results may suggest substandard 
asthma care in Portuguese children, especially in rural areas, where the frequency of lung function tests, 
allergy tests and used inhaled medication were lower. 
Regarding rhinitis in the elderly, despite overall symptoms duration of more than 25 years in the majority 
of the elders and that more than 40% presented moderate-severe disease, only one third of patients with 
current rhinitis had been physician diagnosed and the same percentage had been under treatment for this 
disease in the previous 12 months. The association found between rhinitis and asthma further 
emphasized that overall rhinitis care may be substandard. About 40% of elderly patients with physician-
diagnosed asthma had complaints of current rhinitis but were not diagnosed or treated for rhinitis. This is 
reinforced in those on current treatment for asthma and concurrent current rhinitis, since more than half of 
these patients had no physician diagnosis of rhinitis. Considering that rhinitis symptoms interfere with 
asthma control
(6, 21, 22)
, there should be a greater awareness for the assessment of nasal disease in 
patients with an asthma diagnosis. The fact that a strong association was found between physician-
diagnosed asthma, asthma on current treatment and all ARIA classes of rhinitis further supported the 
importance of an accurate rhinitis diagnosis in the elderly, including in milder presentations. 
After adjusting for independent variables, living with relatives and especially living in a nursing home was 
associated with current rhinitis and also with physician-diagnosed rhinitis and asthma. This may suggest 
that these elderly subjects, compared to those who reside in their own house, could have greater 
frequency of rhinitis and asthma or better access to medical care. The fact that those individuals living in 
their own house had current treatment less frequently may either reflect better disease control in this 
group, or, on the contrary, support the assumption regarding worse access to medical care in elderly 
subjects living in their own house. Yet, it should also be considered that those elderly living in nursing 
homes often have greater deconditioning or multiple co-morbidities, which could contribute for disease 
misdiagnosis. 
We also found regional differences across mainland Portugal. The greater difference between current 
rhinitis and physician-diagnosed rhinitis prevalence was observed in Alentejo. This may be related to the 




reflect lower access to health care in this area. Alentejo is an inland region, also characterized by the 
highest absolute pollen concentrations in mainland Portugal, which occur seasonally, due fundamentally 




Despite our studies limitations, these results can thus support the need to implement new strategies for 
improving awareness management and control of these diseases, aiming at reducing rhinitis and asthma 




Definition of early childhood wheezing phenotypes related to asthma persistence 
The high prevalence of asthma in Portugal, since very young ages, reinforced the need to accurately 
diagnose asthma cases early, with the aim to initiate proper treatment and to reduce the asthma burden 
since its very beginning. Wheezing was a major complaint in children with asthma, especially frequent at 
younger ages. The complexity of diagnosing asthma at early ages may arise from the very distinct long-
term outcomes of early recurrent wheezing in children (author publication – full text available in the 
Attachments sections – number 1)
(74)
. Using data from our cohort study, we developed a 
multidimensional, “unbiased” statistical cluster model that combined different patient characteristics, 
based on questionnaires and skin prick tests, to assess the prognosis of asthma persistence in preschool 
children with recurrent wheezing. This prospective study allowed identifying three distinct early childhood 
wheezing phenotypes, which were predictive of asthma persistence, use of control treatments and lung 
function at school age and adolescence. Atopy and rhinitis were two independent risk factors for asthma 
persistence. 
This study represented the largest cohort of children with recurrent wheezing conducted in Portugal so 
far. The “unbiased”, hypothesis-free, multidimensional statistical modelling of prospectively obtained data 
was important to validate previous international phenotypic classifications in this distinct cohort. In order 
to reduce subjectivity, children with recurrent wheezing were included irrespective of any classifications or 
a priori definitions. The set of variables included in the cluster analysis was exclusively derived from the 
logistic regression model for asthma persistence, which included all study variables.  
This study had the advantage of a long follow-up time (13 years). The children were systematically 
evaluated at key moments of childhood development up to adolescence. We analyzed data for a large 
number of patient characteristics, including respiratory symptoms, personal and family histories of allergic 
diseases, environmental exposures, skin prick testing, and lung function evaluations. All data regarding 
diagnoses were validated by Immunoallergy specialists.  
The main limitations of this study were the loss of participants during follow-up and the lack of objective 
markers for environmental exposures (namely, tobacco smoke) and preventive treatment use. At the end 
of 13 years of follow-up, 55% of the cohort was lost to follow-up. However, the cohort remained 
homogenous in the main baseline characteristics throughout all evaluation time points. 
Furthermore, the sample selection was based on the first visit to a specialized center, which may be 
associated with a bias. However, the sampling strategy provided sample homogeneity with respect to 
clinical manifestations and wheezing frequency and severity. Although atopy at preschool age was 
defined by skin prick test results to a broad number of possible clinically relevant set of aeroallergens and 





considered. In some cases, allergen mixtures were used to limit the number of skin prick tests to perform 
in young children.  
The identification of wheezing phenotypes based on multidimensional statistical modelling of data, without 
predefined criteria allows a less biased classification of wheezing. However, it is important to consider 
that the modelling will always depend on study design, definitions used and on the selected variables and 
clustering method. To be accurate, this modelling strategy is less biased (rather than “unbiased”) than the 
traditional hypothesis-driven clustering. In order to further improve childhood wheeze classification, the 
time dimension should be taken into account, to cope with the recognized variability of asthma. The 
wealth of data from longitudinal datasets requires the application of flexible mathematical approaches to 
model the effects of time-varying factors (namely environmental exposures) and wheeze outcomes with 
multiple trajectories, measured at different time points. Modelling the effect of time-varying with time-
invariant related factors and using the age at data collection as a continuous variable can be possible 
using statistical methods such as latent class growth analysis
(184)
. 
The “unbiased” phenotypic classifications derived exclusively from data can be complementary to groups 
defined a priori or based on directly observable criteria. The Tucson Children’s Respiratory Study was 
one of the most relevant birth cohort studies, designed to determine wheeze risk factors
(59, 65)
. A total of 
1246 new-borns were recruited and the cohort reflected a general population sample. Three wheeze 
phenotypes were defined: persistent atopic wheeze (corresponding to 15% of the whole sample, 
characterized by wheeze onset <3 years of age and persisting at 6 years), late non-atopic wheeze (14%, 
with wheeze absent at the age of 3 years but present at 6 years) and early transient wheeze (20%, with 
wheeze onset <3 years of age but absent at 6 years); 51% of the included children had no wheeze. 
These three wheeze phenotypes have been validated in independent cohorts, namely in France and in 
the United Kingdom, by unsupervised statistical methods
(185, 186)
. Other prospective studies using 
“unbiased” clustering proposed a classification with a higher number of phenotypes
(60, 187)
. Nevertheless, 
all these studies agreed that one of these clusters of children was characterized by having transient early 
wheezing. This phenotype has been associated with viral infections and lower airways caliber. Typically, 
there was no personal or family history of allergic or respiratory diseases. This phenotype has been linked 
to passive smoking and day-care attendance during the first year of life and having older siblings
(65)
. 
These children may exhibit early lung function limitation with airway obstruction pattern that tend to 
improve overtime
(65, 71)
. Consistent with this description, a non-atopic transient wheezing phenotype was 
also found in our cohort, which was associated with not having atopy, rhinitis or atopic dermatitis and no 
family history of asthma, despite early onset of wheezing (<24 months). In our cohort, this phenotype was 
also associated with day-care attendance during the first year of life. Therefore, children with >3 episodes 
of wheezing dyspnea responsive to bronchodilators and symptom-free intervals between exacerbations at 
preschool age can become symptom-free, especially when no other risk factors exist. Notwithstanding, 
most children in our cohort remained symptomatic throughout the study, in contrast with the Tucson study 
that stated that 60% of preschool children with wheezing became asymptomatic by age 6 years
(188)
. This 
difference was most likely due to the distinct sample selection criteria. In the present study, we selected 
children with at least three wheezing episodes over the last 12 months, but the Tucson study only 
required one episode
(188)
. However, we could not exclude the possibility that, in our study, full symptom 
resolution may have occurred more frequently among the children lost in follow-up.  
Opposite to the non-atopic transient wheezing phenotype, the persistent atopic wheeze phenotype was 
characterized by a later onset of wheeze (>24 months) and personal and family history of allergic 
multimorbidity, as previously described
(59, 65, 189, 190)
. This allergic multimorbidity phenotype had the worst 
prognosis related to symptoms persistence in adolescence. Impaired lung function was more common 
than in the non-atopic transient wheezing. It is important to note that despite the different proposed 




atopy was related to symptoms persistence
(60, 65, 185-187)
. In our study, atopy at preschool age was an 
independent risk factor for asthma persistence in adolescence. This reinforces the need to perform 
allergy tests (namely skin prick tests with allergen extracts) at early ages. Allergen sensitization in 
symptomatic children should strengthen the diagnosis of asthma (although atopy is not mandatory for the 
diagnosis)
(6, 191)




Lastly, similar to the non-atopic asthma phenotype described by the Tucson group
(65)
, we have identified 
a third wheezing phenotype that was persistent, yet not associated with systemic atopy. This phenotype 
was less frequent than the atopic persistent wheeze phenotype (only 14% of children from our cohort 
were included in this group) but it was also characterized by worse prognosis regarding persistent 
symptoms, medication use and impaired lung function. Interestingly, although less usually described, 
such a phenotype has also been found in other cohorts
(65, 185, 186, 189, 190)
. Nonatopic persistent wheeze has 
been associated with respiratory infections-related airway hyperreactivity. In our cohort, despite an early 
onset of wheeze and the absence of systemic atopy, these children differed from the group with good 
prognosis in the fact that most had rhinitis. Furthermore, most children had family history of maternal 
asthma and day-care attendance during the first year of life was less frequent. Therefore, unlike previous 
reports
(193-196)
, we found that, independent of atopy, rhinitis at preschool ages was a significant risk factor 
for asthma persistence. Local allergic rhinitis may be involved, defined by the presence of IgE-mediated 
allergy that is only evident in the nasal mucosa, without positive skin prick tests or detectable specific IgE 
in the serum
(26, 27, 197, 198)
, but we did not test these children for local IgE-mediated allergic responses. 
Notwithstanding its high prevalence in preschool children (estimated to be 43% in Portugal), rhinitis 
remains underdiagnosed particularly in children
(199)
. Among preschoolers, the severity of wheezing and 
rhinitis are strongly associated
(61)
. Thus, our results emphasized the need to value and assess nasal 
symptoms in children, independent of atopy, since early ages. Taken together, these results further 
strengthen the need to consider the rhinitis and asthma multimorbidity in clinical practice and also in 
research. 
Preschool eczema was also associated with asthma persistence, as consistently reported
(59, 191, 195, 200)
. 
This inflammatory disease is another feature of the allergic multimorbidity phenotype. However, we found 
that preschool eczema was not an independent risk factor for asthma persistence. This may have 
resulted from the association between eczema and rhinitis and/or atopy. The Asthma Predictive Index 
includes eczema as a major criterion and rhinitis as a minor criterion for predicting asthma 
persistence
(200)
. In contrast, in our study, we identified rhinitis, not eczema, as an independent risk factor 
for asthma persistence. 
Asthma prevalence during school ages and adolescence was higher in children with a maternal asthma 
history. However, there was no association with paternal asthma. Although parental asthma diagnosis 
was only self-reported in the present study, results of other studies indicated that maternal and paternal 
characteristics may have distinct impacts on offspring asthma development
(201, 202)
. In particular, the 
maternal influence on gene-environmental interaction was greater than paternal influence regarding IgE 
production and asthma development. Exclusive exposure to maternal environmental factors during fetal 
development, fetus-maternal shared perinatal environment exposures (including breastfeeding), different 
hormones and genomic imprinting are possible explanations for the mother/father different impacts on 
asthma development of their offspring
(203)
.  
Children who attended day care during infancy had significantly fewer persistent symptoms. However, 
this “protective” effect seemed to be lost with age; no effect was observed in adolescence. Also, day care 
attendance frequency was similar among the worse prognosis atopic persistent and the better prognosis 





attendance at early ages may depend on other characteristics of the children in each group. This 
hypothesis may be consistent with previous studies that demonstrated that the protective effects of day 
care attendance with respect to allergen sensitization and respiratory symptoms depended on genetic 
variants
(204)
. In two independent unselected birth cohorts from distinct geographic areas, the association 
between day care attendance and sensitization/atopic wheezing appeared dependent on a genetic 
variant in toll-like receptor 2 gene. Day care attendance was protective to those children with the T allele 
for toll-like receptor 2/-16934, whereas in those who were AA homozygotes the association tended to be 
in the opposite direction
(204)
. In complex diseases such as asthma, genetic predisposition may need to be 
taken into account when assessing the effect of environmental exposures and not all individuals may 
benefit from a specific intervention. 
Exposure to maternal tobacco smoking during pregnancy is a major concern, and it has been associated 
with asthma in children in several studies
(201, 205-209)
. Despite a significant trend over time that showed a 
decreasing frequency of asthma in children without maternal smoking during pregnancy, our results could 
not confirm that association. Similarly, we found no association between environmental tobacco exposure 
and asthma persistence. However, it is important to stress that, in this study, exposure to tobacco smoke 
was only self-reported; it was not objectively measured, and, thus, the results may be significantly biased. 
Lung function abnormalities were associated with asthma persistence in adolescence. Nonatopic 
persistent wheezing had the worst prognosis in lung function parameters during school age and 
adolescence. Our results indicated that children with early wheezing onset were at risk of asthma 
persistence and lung function impairment when associated diseases were present, namely rhinitis, or 
when there was a family history of maternal asthma, even in the absence of atopy. Cohort studies have 
acknowledged atopy as a determinant of lung function
(193-195, 210)
, but rhinitis alone, without atopy, has not 
been reported. However, a recent publication demonstrated that lung function trajectories were 
associated with asthma combined with comorbidities rather than with allergen sensitization
(209)
. Assuring 
adequate lung function development throughout each child’s growth is critical. Early childhood-onset 
wheezing that persists into adolescence represents the clearest target group for interventions to 






Biomarkers in allergic rhinitis and asthma multimorbidity in children 
The previous studies further extended the data on the association between rhinitis and asthma. Children 
with the worst prognosis of asthma persistence until adolescence were the ones with allergic rhinitis and 
asthma multimorbidity, reinforcing the need for integrated clinical approaches. 
 
Integrating care pathways with biomarkers – adding nasal function in the concurrent evaluation of 
allergic rhinitis and asthma control?  
Integrated care of patients with concurrent rhinitis and asthma is essential at the clinical level
(6, 7, 22)
. The 
subjective assessment of symptoms is crucial to evaluate severity and control of rhinitis and asthma 
multimorbidity. Objective markers complement this subjective assessment. Lung function parameters 
support asthma diagnosis and future risk assessment, and are currently recommended to be performed 






Likewise, objective measures of nasal function have been recommended
(84, 85)
, and successfully used for 
the objective evaluation of rhinitis and its control
(89-92)
, including in children
(93, 94)
.  
In our exploratory study, we analyzed the PNIF of healthy children and children with allergic rhinitis and 
asthma multimorbidity, which is the simplest validated method to assess nasal function
(84, 85)
. We found an 
anthropometric independent correlation between PNIF and PEF and FEV1 in school-aged children (6 to 
12 years). Our results suggested that, ideally, at least PEF values should be considered, besides age and 
gender, when evaluating nasal function by means of PNIF in this age group. Furthermore, this study 
strengthened that the objective measurement of nasal flow and subjective symptoms scores may not be 
correlated. We described, for the first time, no associations between PNIF and the CARATkids 
questionnaire scores, except for nasal obstruction self-report in the past two weeks and PNIF expressed 
in z-scores in children with allergic rhinitis and asthma. Therefore, these results suggested that, similarly 
to lung function parameters in asthma, PNIF can provide complementary objective information to 
subjective control assessment in children with allergic rhinitis and asthma multimorbidity. 
We hypothesized that PNIF was associated with PEF and FEV1, independent of anthropometric variables. 
This had not been published before in this age group but it is critical for an accurate interpretation of PNIF 
values in children. Sequential upper and lower airway standardized evaluations of the same individual 
were performed, reporting PNIF values before and after nasal topical alpha-adrenergic use and PEF and 
FEV1 values before and after inhaled beta2-agonist. A balanced sample of patients comprising different 
asthma control levels was studied, together with age and gender-matched healthy controls. Consistent 
correlations between upper and lower airway flow were found. These correlations persisted after 
adjusting to age, gender, height and weight, suggesting that the association between upper and lower 
airflow measures is independent and not a simple reflection of children’s growth or body size. The 
correlations found between PNIF and PEF expressed in z-scores (which is an age, gender and height-
independent variable) also supported our conclusions.  
This study’s main limitation was its cross-sectional and exploratory design. Further studies with larger 
heterogeneous samples are needed but our results suggested the need to include at least PEF, besides 
age and gender, in these future studies concerning PNIF reference equations in this age group. Our study 
did not include children with rhinitis or asthma alone. Most children with asthma have rhinitis and we did 
include asthmatic children with different levels of disease control and lung function tests results, but the 
inclusion of children with asthma or rhinitis only is relevant for generalization of the results to these 
groups of patients. Another limitation is the lack of children of other ethnicity, which limits our results only 
to Caucasians. Despite the fact that all diagnoses were validated by medical specialists (based on 
anamnesis, clinical files and medical examination including anterior rhinoscopy), no nasal endoscopy or 
imaging techniques were performed in this study. Therefore, we could not firmly rule out adenoid 
hypertrophy or nasal septum deviation (which could introduce biases into our study), but only excluded 
children with known or suspected diagnosis or with observable anatomical nasal abnormality on anterior 
rhinoscopy. 
The fact that nasal flow can be influenced by lower airway status has long been a concern
(85)
. Studies in 





initially considered a limitation of PNIF, the concept of a single disease of the airways in rhinitis and 
asthma multimorbidity has changed this view, and the impact of the lower airways is now taken into 
consideration in the study of nasal function
(85, 212)
. The correlation between PNIF and PEF has been 
reported in healthy children
(98)
, but no multivariable analysis including PEF values was reported and FEV1 
wasn’t evaluated. As previously described
(96-98)
, we have found a correlation between PNIF and age, 
height and weight. PNIF values were higher in boys compared to girls but, as reported by Papachristou et 
al, this difference did not reach statistical significance until the age of 12 years
(96)
. Since age was the only 
variable consistently reported in the literature to be correlated with PNIF
(95-99)





for PNIF using this variable were presented. We chose to include baseline PEF rather than FEV1 in the 
final model since baseline PEF is more easily obtained, even with only a peak flow meter and without the 
need to use bronchodilators. After accounting for these variables, there still remains a large degree of 
variability in PNIF values, suggesting that further variables, such as anatomic variations or possibly nasal 
inflammation may refine the modelling of data. 
Using acoustic rhinometry (before and after alpha-agonist) and spirometry with bronchodilation test, 
Chawes and collaborators found an independent and consistent correlation between nasal volume and 
FEV1 in children aged six years
(213)
. In accordance to our results, the correlation between upper and lower 
airways measures were observed independently of rhinitis and asthma diagnosis
(213)
. This suggests that 
the independent correlation is a consistent finding in healthy and asthmatic children. Our results further 
support the hypothesis that the correlation between upper and lower airways may reflect a physiologic 
background for the common rhinitis and asthma multimorbidity
(213)
. 
Pathologic mechanisms could also be involved. A continuous nasobronchial inflammation process has 
been described in rhinitis and asthma
(21, 23)
. However, we found no association between PNIF and FeNO 
levels or between reversibility of the upper and lower airways, also in agreement with Chawes et al 
findings
(213)
. We also found no differences in PNIF according to multiple sensitization to aeroallergens, as 
described before
(213, 214)
. Nevertheless, Chawes and collaborators reported an association between blood 
eosinophil counts and nasal eosinophilia with nasal patency
(213)
, which we did not evaluate.  
Reference values for the pediatric population have been published, all measured in non-decongested 
noses
(95-99)
. Yet, it is important to measure PNIF values before and after decongestion to elicit the role of 
mucosal swelling
(84, 85)
. Our baseline PNIF values were similar to the reported values in healthy children in 
Brazil
(97, 98)
. Prescott et al and van Spronsen et al reported slightly lower PNIF values
(95, 99)
, while 
Papachristou et al, who analyzed the largest sample of healthy children, reported higher PNIF values
(96)
. 
The discrepancy between study results could be due to different studied populations and to different 
methods (for instance, not performing the PNIF maneuver from the residual volume until reaching total 
lung capacity
(95)
, or PNIF values collected while sitting
(95, 99)
, or standing up
(96-98)
). A recent study in adults 
showed a trend towards a positive effect of the standing position on PNIF, although not statistically 
significant
(215)
. To our knowledge, the effect of body position on PNIF in children has not been analyzed. 
Papachristou et al published PNIF values were similar to our observed decongested PNIF values
(96)
, 
which we used as a reference. 
Data regarding the association between CARAT questionnaires and objective measures of nasal function 
did not exist before this study. Nevertheless, previous studies with children have found an agreement 
between objective and other subjective measures of nasal obstruction
(93, 216)
, while other researchers 
reported the opposite
(217)
. The reason for this disagreement in multiple studies is probably multifactorial. 
For instance, given the known influence of other variables including age, gender and anthropometric 
variables in upper airway function in children, it is important to use reference values to obtain predicted 
percentages or ideally z-scores to interpret the results. We found an association between PNIF 
expressed in z-scores (for age and gender) and nasal obstruction self-report in the CARATkids 
questionnaire in children with allergic rhinitis and asthma. This association was also independent of PEF. 
Evaluating each nostril individually instead of bilateral measurements has been shown to allow stronger 
correlations between objective and subjective measurements in adults
(87)
, and also described in children 
using rhinomanometry
(217)
. On the other hand, the subjective scoring tool influences the results. Scales 
with fewer score options seem to increase the probability of an association between objective and 
subjective measurements
(218)
. The exact questions and time of symptoms evaluation may also affect this 
association. In our study, we didn’t find statistically significant differences in PNIF comparing healthy 
children and children with rhinitis and asthma reporting nasal obstruction in the CARATkids questionnaire. 




CARATkids questionnaire considers nasal symptoms self-reported by the children regarding the last two 
weeks and not necessarily current symptoms at the time of PNIF measurement. Moreover, in a previous 
study in adults, patients with asthma significantly rated their nasal obstruction by visual analogue scale 
more seriously than non-asthmatic controls with comparable PNIF values
(101)
. Apparently, the sensation 
of nasal obstruction in asthmatics may be different from controls despite being in the same PNIF 
group
(101)
. On the opposite direction, children on long-term treatment for chronic rhinitis may underreport 
the amount of nasal congestion
(219)
, and it has been reported that children may be more accepting of 
mouth-breathing than adolescents
(218)
. Last but definitely not least, children might also be influenced by 
their parents or guardians’ perceptions during the subjective assessments, which may also contribute to 
this disagreement
(217)
. Therefore, as in asthma, objective and subjective assessments appear to evaluate 
different parameters that may not be directly related, and PNIF may provide complementary information 
to the subjective evaluation of rhinitis and asthma in children. Since the subjective feeling of nasal 
obstruction may be valued differently by individual subjects, future research studies addressing PNIF in 
children with rhinitis and asthma may take advantage of additional comparisons with other measures of 
nasal patency, namely using the “golden standard” rhinomanometry. 
 
 
”Unbiased” molecular phenotyping – contributing to the link between clinical phenotypes and 
disease endotypes?  
According to the current paradigm, asthma should not be regarded as a single disease, but rather as a 
complex syndrome. The “allergic asthma” (as defined by GINA) is a classic form of persistent asthma, 
with a typical childhood onset, accompanied by allergic features, including sensitization to allergens and 
allergic rhinitis
(6, 220)
. Cluster analyses of asthma phenotypes also support the existence of childhood 
onset “allergic asthma” as a distinct endotype
(28, 29, 220, 221)
. 
Our case-control study explored the potential of untargeted metabolomics to uncover “unbiased” 
differentiating metabolic features of allergic rhinitis and asthma multimorbidity in children. Using NMR 
exploratory metabolomics, differentiating subsets of NMR spectral areas in urine and saliva were found. 
Some of these metabolic variables were associated with such clinical readouts as lung function 
parameters, FeNO levels and multiple allergenic sensitization. The identification of the metabolites 
contributing to these differentiating variables further supported several hypotheses, namely regarding the 
role of arginine, taurine, quinolinate and butyrate in allergic rhinitis and asthma multimorbidity. Our results 
require validation and these hypotheses will need further analyses. 
At variance with most of the previous metabolic profiling studies, we used untargeted metabolomics to 
uncover “unbiased” differentiating metabolic features of a specific clinical phenotype and considered 
allergic rhinitis and asthma multimorbidity for the first time. Furthermore, we have used two non-invasive 
samples, collected consecutively from each child, aiming for a more “systemic view”. A balanced sample 
of patients comprising different asthma control levels was studied, together with age and gender-matched 
non-atopic healthy children. All diagnoses were validated by specialist medical doctors and all children 
were characterized regarding airway inflammation measured by FeNO and lung function with spirometry 
and bronchodilation test. Spectral NMR areas of urine and saliva were associated with allergic rhinitis and 
asthma using statistical analyses that involved a pre-selection of variables followed by linear modelling. 
Compound identification was performed, to benefit possible methodology validation, as well as raising 
pathophysiological hypotheses. 
Molecular profiling by untargeted approaches may provide novel insights to characterize clinical 





strategy may bring complementary data to our current knowledge and to the results of hypothesis-driven 
studies (author publication – full text available in the Attachments sections – number 2)
(104)
. Similarly to 
the “unbiased” clustering methods discussed before, it is important to acknowledge that untargeted 
metabolomics results will always depend upon the participants’ inclusion criteria, study design, samples 
procedures and on the analytic technique and its intrinsic analytic coverage. With the inclusion of a high 
number of patients in heterogeneous populations, these untargeted “omics” analytic technologies can be 
used to find relevant molecular clusters and potentially contribute to improve our classification of the 
diseases. However, exploring the molecular profiling of a clinically defined asthma phenotype may reduce 
heterogeneity and potential bias. In fact, one probable justification for the distinct results obtained so far 
by the existing metabolic profiling studies in asthma may rely on the distinct study populations, especially 
considering the heterogeneity of asthma
(222)
.  
The “allergic asthma” phenotype is the most commonly recognized asthma group in childhood. Although 
this is the best described asthma phenotype, a curative treatment is lacking and still heterogeneity exists 
in patients’ clinical presentation, disease severity and response to therapy
(6, 223)
. Atopy is an important 
feature that explains some but definitely not all the mechanisms involved. Apart from the involvement of 
the adaptive immune responses to allergens in a typical Th 2 and IgE-driven disease, more recent insight 
also highlighted a major involvement of innate lymphoid type 2 cells, producing type 2 cytokines in 
response to other common triggers such as pollutants and viruses that coexist and interact with 
allergens
(224)
. The view of eosinophilic asthma as an exclusive allergic Th2 or non-allergic innate lymphoid 
type 2 cell disorder (and even the exclusive neutrophilic Th1 and/or Th17 disorder) represents an 
oversimplification. It is important to consider the dynamic overlap of mixed cell types and cytokines 
contributing to the disease that occurs in each asthma patient
(75)
. 
Exploratory metabolomics aims to provide a global snapshot of all small-molecule metabolites in 
biospecimens, free of observational biases inherent to more focused studies of metabolism. A hallmark of 
metabolic fingerprint is the use of multivariable analysis to identify class differences in highly complex 
datasets. The Principal Component Analysis (PCA) is the most commonly used statistical method. 
Spectral features contributing most to data variation or separation are identified for further analysis. The 
unsupervised nature of the PCA algorithm only reveals group structure when within-group variation is 
sufficiently less than between-group variation. In our study, the first two components of the obtained PCA 
model explained only 17% and 33% of the variation of the urine and saliva data, respectively. Neither 
rhinitis and asthma, nor asthma control contributed to the main sources of variation of the data in both 
urine and saliva models. This may be due to the fact that the broad range of the metabolome that can be 
captured by metabolomics profiling is sensitive to both internal and external influences that may be 
unrelated to disease status. It could also reflect heterogeneity in allergic rhinitis and asthma-related 
metabolic pathways or even still limited analytical coverage or discriminatory capacity to identify global 
shifts in multiple correlated metabolites. Yet, this does not mean that there are no variables of interest to 
differentiate asthma in these biospecimens. In fact, similar findings have been described by the different 
research groups using different biospecimens including urine, saliva and other samples such as plasma 
and EBC in multivariable analyses in asthma profiling studies
(110, 121, 123, 225-229)
. Feature selection can 
allow for the extraction of important metabolites
(107)
. This is applied to: a) reduce overfitting, b) improve 
model performance and c) gain a better understanding of the relationship between the metabolic features 
and the response clinical variable. Several feature selection strategies have been used by different 
research groups to identify metabolic discriminatory features classifying asthmatics from healthy controls. 
For instance, metabolites summary scores have been created based on spectral variables shown to be 
associated with asthma status by removing spectral variables listed as being lower in significance on the 
variables of importance plot until a pre-set false-positive rate for healthy individuals
(225, 226)
, or until a 
maximum goodness of prediction were reached
(123)
. We chose univariable spectral area selection to 




interpret less biased approach
(227, 229-231)
. These preselected sets of variables were further reduced by 
linear modelling and logistic regression was applied to select the final best set of spectral areas. As 
response variable, comparisons were made between healthy children and children with partly controlled 
and uncontrolled asthma, since more significant differences were expected to be found than in controlled 
asthma. Since partly controlled and uncontrolled asthma may be metabolically heterogeneous 
themselves, separate models were built for each group. In fact, by using this approach, different subsets 
of spectral areas and different metabolites were identified that differentiate the two groups, except for 
pantothenate which was identified in urine as a relevant differentiating metabolite in both models. Distinct 
from previous metabolic profiling studies in asthma, we analyzed saliva and urine simultaneously from the 
same subject, but found distinct differentiating metabolites subsets in the two samples. However, some of 
the identified metabolites were indeed common to previous metabolomics profiling studies and have been 
linked to asthma. In particular, arginine and fatty acid metabolism are common reported pathways in 
asthma metabolomics studies, regarding both experimental animal models of allergic airway 
inflammation
(232-235)
, and clinical studies in humans
(116-118, 120, 122, 225)
 (author publications – full text 
available in the Attachments sections – numbers 3 and 4)
(105, 106)
. 
An enrichment of pathways reflecting increased metabolism of amino acids in asthma has been 
anticipated
(108)
. Amino acids are mediators of immunological activities in asthma and may have 
antioxidant functions, namely taurine
(115, 116)
. Urinary citrate has been previously reported to reduce during 
asthma exacerbations
(236)
. Low systemic arginine levels have been described in asthmatics
(118, 237)
. 
Decreased levels have been associated with induction of arginase activity in asthma, an enzyme that can 
be induced by type 2 cytokines
(238, 239)
. Arginine can also act as a substrate for nitric oxide production
(240)
, 
but we found no association between salivary arginine and FeNO levels. In fact, increased levels of FeNO 
in asthma could reflect metabolism of arginine from a compartmentalized pool in which arginine content is 
not reflected by systemic arginine levels, as supported by arginine increased levels in EBC and 
pulmonary tissue
(117, 241)
. Other arginine-independent sources of FeNO need also to be considered, 




Although we found that these amino acids discriminated asthmatics, the link with the reduced level of free 
metabolites in the saliva and asthma is unknown. This could be related to systemic levels but also to 
dietary changes or salivary gland secretion. Of relevance, taurine is the most abundant free amino acid, 
mainly in proinflammatory cells and tissues exposed to elevated levels of oxidants, such as the salivary 
gland, where it exerts a role in regulation of salivary flow. Altered salivary flow rates have been described 
in asthmatics, which can contribute to changes in saliva composition
(244, 245)
.  
Quinolinate is an endogenous metabolite of tryptophan at the kynurenine pathway, which has been linked 
to inflammatory pathways
(246, 247)
. Quinolinate may also derive from alanine, aspartate and glutamate 
metabolism and be involved in nicotinate and nicotinamide metabolism, precursors for generation of 
coenzymes nicotinamide adenine dinucleotide and nicotinamide adenine dinucleotide phosphate. These 
coenzymes are crucial in many metabolic pathways including glycolysis, tricarboxylic acid cycle and fatty 
acid metabolism. The synthesis of nicotinate from tryptophan is possible but it is a slow and largely 
inefficient process. Quinolinate levels were found to be higher in serum and lower in EBC in adult patients 
with allergic asthma
(248)
. Moreover, systemic quinolinate has been associated with eosinophilic cation 
protein and eosinophils in bronchoalveolar lavage fluid, and peak asthma symptom scores after rhinovirus 
challenge
(248)
. Interestingly, besides a negative correlation with lung function parameters, we also found a 
positive association between urinary quinolinate levels and multiple allergenic sensitization and FeNO 
levels, which could further support quinolinate as a marker in the type 2 inflammatory pathway
(248)
. 
However, the pathophysiologic mechanisms of enhanced systemic quinolinate in asthma remain to be 







. The immunomodulatory function of indoleamine 2,3-dioxygenase, the rate-limiting enzyme in 
tryptophan catabolism, and other compounds generated during tryptophan metabolism have also been 
described in asthma, supporting that further insights on this metabolic pathway may contribute to 
increased knowledge in asthma
(115, 246, 248-250)
. 
Butyrate has also been identified in exploratory metabolomics studies in asthma
(120, 122)
. This molecule is 
a short chain fatty acid, mostly produced in humans in the gut by anaerobic fermentation of undigested 
carbohydrates and fiber polysaccharides. Besides its role in the energy requirement, butyrate is 
suggested to be a mediator in the communication between commensal microbiota and the innate and 
adaptive immune system, with multiple anti-inflammatory effects, including suppression of nuclear factor 
kappa B activation and interferon gamma production, upregulation of peroxisome proliferator-activated 
receptor gamma and promotion of peripheral regulatory T cell generation, affecting effector cells 
migration, adhesion, proliferation and apoptosis
(251-255)
. It has been recently reported that butyrate can 
influence type 2 innate lymphoid cells proliferation and function, associated with reduced airway 
hyperreactivity and inflammation in mice
(256)
. The principle mechanism of action involves epigenetic 
regulation through the inhibition of histone deacetylase
(251)
. Overall, histone deacetylase inhibitors have 
been recently considered in the treatment of asthma and other inflammatory lung diseases
(257)
. The lower 
levels of butyrate were associated with partly and uncontrolled asthma and impaired lung function. Taken 




In our study, using the identified differentiating spectral regions subsets, the obtained summary scores 
showed good classification accuracies. While some metabolites associated with allergic rhinitis and 
asthma in our study are biologically plausible and supported by previous experimental data, these 
preliminary results require validation. This step is critical to assess true discriminatory ability and support 
for accuracy of the reported biomarkers in independent cohorts. Furthermore, essential steps relate to 
monitoring external factors that may affect the metabolome and introduce significant bias to the results. 
This is important in any study design, especially when using such multivariable analytical techniques as 
NMR or mass spectrometry. External factors known to affect the metabolome include the age, gender, 
body mass index and circadian rhythm. Despite being well matched demographically (age, gender, body 
mass index) and all samples being collected at the same time of the day, it is important to highlight that 
diet and current asthma treatment may have interfered with the urine and saliva metabolic profile in our 
study. Although care has been taken to refrain from drinking or food intake before samples collections 
and most medication was inhaled and had been stopped for at least 12 hours, we cannot firmly rule out 
that our results were not affected by diet or medication. Nevertheless, no association was found between 
any differentiating spectral area and self-reported specific food intake or fasting time or drug use on the 
previous week, except for oral montelukast, which was associated with the variable comprising arginine 
and taurine in saliva. However, an explanation for this association is unknown to us, considering that 
montelukast had been taken more than 36 hours before saliva collection. Randomized trials and animal 
model studies analyzing the effect of medication on the metabolic profile will help distinguishing the effect 
of drugs from the disease effect on the metabolome
(106)
. After accurate validation of the results, we should 
be able to contribute to the rather incomplete and imprecise figure of relevant metabolic pathways in 
asthma pathogenesis (Chapter 1 – Figure 6), namely in the more specific clinical phenotype of childhood 
allergic rhinitis and asthma multimorbidity. Last, but definitely not least, while aiming to uncover 
differentiating features of a given disease or state, the determination of specificity of a given potential 
biomarker also needs to be analyzed. It is important to consider that many metabolites that have been 
reported to be associated with asthma in exploratory metabolomics have also been found in other 
diseases, namely cystic fibrosis, acute respiratory distress syndrome and even multiple malignancies
(108)
. 
While this does not negate their possible involvement in asthma pathogenesis, it questions their role as 




We further assessed potential exogenous contaminants in EBC exploratory metabolomics analysis. 
Endogenous and microbial components in exhaled breath have the potential to contribute to the 
metabolic profiling of asthma. However, components in exhaled breath also originate exogenously
(113)
. 
Potential misinterpretation and inconsistency between study results may occur if the origin of certain 
metabolites in EBC is assumed as endogenous and thus considered useful biomarkers in asthma, 
despite the possibility of being originated exogenously, namely from the environment. Eliminating 
metabolites originated in the inhaled air from EBC can be particularly challenging and complex. According 
to recommendations, control experiments in which subjects inhale filtered or specific air mixtures that do 
not contain the specific compounds, or their precursors, that will be measured should be considered
(112, 
113)
. This strategy may be insufficient given all the possible interactions of different air compounds with the 
molecules of interest, and it is not feasible in untargeted “omics” approaches where no compound 
preselection is done before data analysis. Despite the recommendations to address potential 
environmental contamination, this has not been routinely reported in many EBC metabolic profiling 
studies. However, based on the results of our study comparing air samples with human EBC samples, we 
reinforce the need to report ambient air controls during EBC samples collection and address the influence 
of exogenous contaminants.  
In a seminal paper on NMR profiling of EBC, Bertini et al used a homemade EBC collecting device
(260)
. 
Humidified room air was pulled into the condensing apparatus and the analysis of this sample resulted in 
NMR spectra free of ambient air or device contamination signals, while an EBC metabolic profile was 
found
(260)
. However, the need to control for ambient air in NMR-based studies had been previously 




Izquierdo-Garcia et al have reported the 
presence of a number of exogenous compounds in the room air samples, including, among other 
components, acetate, formate, propionate, lactate, benzoate, glycerol and propylene glycol
(261)
. In our 
study using a different standard commercial device (R-Tube
®
), the composition of the room air spectrum 
was similar to the one from EBC. Several reasons could be considered to explain our results, from 
ambient air contamination to the effects of the condensing equipment and samples storage or processing 
methodology. Although the influence of each of these factors has not been analyzed individually, our 





 collection system is made of inert, polypropylene materials and a silicon rubber 
one-way valve, and the NMR spectra of water from this collecting system has been shown to be clearly 
different from EBC spectra
(262)
. These strengthened a possible contamination of room air and EBC 
samples in our study. A number of possible factors could have contributed to the contamination, namely 
the limited space in the collection room, insufficient room ventilation and the exhaled breath of the 
assisting personnel. The need to control ambient air may be especially relevant when portable EBC 
collection systems such as the one we used in our study, are utilized in different environments, namely at 
patients houses, schools or work places. A case-control study design under standard procedures has 
been pointed as a solution that could minimize the effect of potential environmental contaminations, 
assuming that these should be randomly distributed between the groups of interest
(229)
. However, NMR 
spectral signals from ambient room air collected in the same place on different days and time of the day 
have been reported to be significantly different
(261)
. Unless all EBC collections were performed 
simultaneously, the case-control design may not be sufficient to guarantee homogeneity considering 
ambient air variability. Validation of findings with an independent cohort of cases and controls also 
minimizes the effect of potential confounders, but still requires confirmation in different environments. 
Thus, other approaches need to be considered during EBC collection. Subtracting the air background 
from the breath signal is a method that is being increasingly applied in gas-chromatography coupled with 
mass-spectrometry breath analysis, by measuring the alveolar gradient, i.e., the relative abundance of the 
metabolites in exhaled breath and in ambient air. Data interpretation is based on the assumption that 





based metabolomics data, in particular given the high correspondence of both spectra, as previously 
reported
(261)
. A common limitation of NMR is its relatively low sensitivity compared to mass-spectrometry 
based techniques. Currently, metabolites with concentrations lower than 0.5-1.0µM will usually be below 
the detection limit. Because of the difficulty of deconvoluting the peaks to quantify individual components, 
NMR metabolomics are often performed in a non-targeted fashion
(263)
. These can make discriminating 
exogenous from endogenous metabolites in EBC more difficult. Another approach is to consider 
fractioned EBC sampling. Commercial devices are currently available that allow the collection of different 
EBC fractions according to a pre-set threshold volume into upper/lower airways or airway/”alveolar” 
fractions. Based on exhaled carbon dioxide profiles, collecting only late-expiratory or end-tidal breath 
involves discarding the initial portion of exhaled breath (estimated dead space, phase I of exhaled breath, 
where carbon dioxide levels are low) or both dead space and transition phase (phase II) of exhaled 
breath, respectively. This collection method aims at a greater relative contribution of endogenous 
compounds in the resultant samples
(264)
. However, this method is not standardized. Concerns regarding 
reproducibility also arise due to distinct physiological properties of individuals including cardiac output 
besides pulmonary ventilation, breathing pattern and expiratory flow rate, which may alter metabolites 
concentration. So far, no qualitative differences were observed between the EBC fractions, although 
distinct metabolite concentrations were found
(264, 265)
. Moreover, airways metabolites may be lost when 




The use of a filter applied to the EBC collection system has also been tried
(117, 120, 261)
. Izquierdo-García et 
al placed a trap for room air contained water-soluble organic compounds in the collecting system. 
Although most of the spectral air signals were removed, NMR signals were still visible
(261)
. Motta and 





. With this strategy, the NMR spectra of condensed room air 
were devoid of signals, independent of the sampling device, while several NMR signals were reported in 
EBC samples
(117, 120)
. Thus, the use of high efficiency filters against particles with approximately 0.3µm 
mass median aerodynamic diameter might be a solution to address ambient air contamination in NMR-
based studies, which deserves further analysis to check external validation in different environments. 
However, this provides no insight into the composition of room air inhaled by a patient. Another possibility 
would be the use of a standard air source during EBC collection. Although variable interaction between 
this source of air and EBC is inevitable, this procedure would allow standardization and independence 
from room air variability. Still, a sensitive analytical method that allows the distinction of exogenous from 
endogenous metabolites is necessary. In summary, our results reinforce the need to report ambient air 
controls collected simultaneously with EBC in metabolomics studies. A careful assessment of any 
potential contamination arising from ambient air or sample collecting and processing procedures is 
essential and NMR may not be adequate to discriminate exogenous from host and microbiome-originated 











Chapter 6: Conclusion and Future Perspectives 
The population-based nationwide epidemiologic studies were important to contribute with estimates on 
asthma prevalence and analysis of its association with rhinitis in two internationally data-lacking 
population groups: the children and the elderly. As an overall conclusion, these studies supported that 
asthma was a common disease, frequently associated with rhinitis, in both age groups. Our results further 
reinforced the need for a greater awareness towards asthma and rhinitis in a clinically integrated, global 
multimorbidity assessment, also in children and in the elderly. 
The prospective cohort study supported the heterogeneity of recurrent wheezing in preschool aged 
children with distinct long-term outcomes. The data-driven defined preschool wheezing phenotypes 
included combined features from other previously described phenotypic classifications. Atopy and rhinitis 
at preschool ages were assigned independent risk factors for asthma persistence in adolescence. Early 
wheezing in children with associated diseases, particularly rhinitis (with or without allergen sensitization), 
tended to predict a worse prognosis of symptoms persistence and lung function impairment in later 
childhood and adolescence. Our study results favored that wheezing phenotypes identified at early ages 
from simple measurements could predict asthma persistence and lung function outcomes, which 
indicated the need for distinct management approaches. 
A proactive integrating strategy to assess and control asthma together with rhinitis demands for 
biomarkers in the multimorbidity context. The objective evaluation of nasal function can reach global 
dissemination in clinical practice, using simple, non-invasive methodologies such as PNIF measurements. 
Our study extended the data supporting PNIF as complementary objective information to subjective 
allergic rhinitis and asthma control and contributed to suggest the need to consider, at least, age, gender 
and PEF when interpreting PNIF in school-aged children. The physiologic background for the common 
rhinitis and asthma multimorbidity was further reinforced. 
Aiming to characterize the rhinitis and asthma multimorbidity at the molecular level, an untargeted 
metabolomics approach by NMR in non-invasively collected samples was explored. Several setbacks 
were found, mainly regarding EBC profiling, which is known to be a highly variable matrix and is 
dependent on ambient air during sample collection, prompting the need to consider these potential 
biases. Saliva and urine are far from being “ideal” samples, but our study further extended the data on the 
potential of untargeted metabolomics of these non-invasive samples in uncovering “unbiased” (less 
biased) differentiating metabolic features of allergic rhinitis and asthma in children. The identification of 
the metabolites contributing to the differentiating subsets of NMR spectral areas benefits future validation 
of the results. It may also support several pathophysiological hypotheses, namely regarding the role of 
arginine, taurine, kynurenine and fatty acids metabolic pathways in allergic rhinitis and asthma 
multimorbidity. 
The work performed in this dissertation, with its strengths and limitations discussed before, achieved 
some contributions but generated many more questions deserving to be answered. These include several 
current unmet needs in asthma and its association with rhinitis, namely: 
- The need to define standardized operational definitions of asthma and rhinitis to be used in 
epidemiologic studies. While this is not uniformly used, one possible solution is to use composite 




estimating asthma prevalence and the elderly study estimating rhinitis prevalence. The use of such 
composite measures allows better comparisons with different research groups and also to estimate 
trends in the prevalence of the diseases and their symptoms. Nevertheless, the clinical validation of 
epidemiologic definitions is essential for accurate estimates. With this aim, the Control and Burden of 
Asthma and Rhinitis study (Impacto e Controlo da Asma e da Rinite – ICAR) combined questionnaire 
answers with medical doctors’ evaluation and a comprehensive set of diagnostic tests, namely 
allergy testing together with nasal and lung function testing in a population-driven sample. This study 
has been designed to validate the survey instruments used in the INAsma study with clinical and 
objective tests and to assess and compare the burden of these diseases. We have recruited and 
included 263 subjects in Lisbon and Tagus Valley region in a total of 858 participants from mainland 
Portugal, and are currently analyzing the collected data. These should be important for the design 
and implementation of future studies to address asthma and rhinitis trends over the years. 
 
- The need to define strategies for an integrated awareness of rhinitis and asthma in all age groups 
and increase these diseases control. Population needs should be analyzed to increase effective 
medical care (especially in rural areas). The ICAR study will further contribute with accurate data on 
the burden of these chronic diseases to set up evidence-based health policies, as it will allow to 
assess the effects of the diseases and their control, comparing patients with asthma or rhinitis alone, 
those with rhinitis and asthma multimorbidity and those without history of respiratory diseases. 
Several health policy strategies may be considered but they should be centered in people’s needs 
and concerns, which are critical to an effective successful reduction in the burden of these diseases. 
These should simultaneously promote greater awareness and facilitate the access to accurate 
information on asthma, rhinitis and allergic diseases. Therefore, it is important to support patients 
associations and scientific societies, being closer to the general public. Strategies may take profit 
from the media, applications (“apps”) and social networks, which are nowadays powerful tools to 
spread the (accurate!) word with simple and clear messages, approximating the general population 
to healthcare, as well as assessing population needs
(41, 42, 267)
. Spreading the knowledge and best 
medical practice on these diseases to medical students and to primary and secondary care 
physicians, with a strong investment in education and update, including the use of straightforward 
developed tools and flowcharts emphasizing patient-reported outcomes
(81, 268-270)
, and facilitating the 
interaction among primary care and immunoallergy specialists can be important to reach patients at 
the nationwide level as well as to deliver best quality individual patient care. 
 
- The need to further address the utility of evaluating nasal function in children. PNIF has the 
advantage to be cheap, simple and suitable for serial measurements of nasal function. However, 
more studies are needed to establish reference values and equations in pediatric age for non-
decongested and decongested PNIF values. The evaluation of nasal flow using PNIF compared to 
other nasal function tests for diagnostic purposes and control assessment / monitoring of nasal 
obstruction needs to be further analyzed at the clinical level, to settle its role in every outpatient clinic 




- The need to continue to pursue the characterization of asthma phenotypes and definition of 
endotypes. Our ongoing analyses of urine and saliva samples by gas-chromatography time-of-flight 
mass spectrometry are currently being undertaken in partnership with the team of experts from the 
Department of Chemistry of Aveiro University. This work will allow the combination of the NMR and 
the mass spectrometry results. Coupling these two techniques to study the metabolic profile of 
different samples from the same individuals greatly broadens the level of metabolite coverage that 
can be achieved, providing complementary information to define differentiating metabolites of 







validation is challenging but necessary in independent cohorts of biological samples, which should 
follow. Procedure standardization is mandatory and external factors affecting the metabolome need 
to be monitored. In order to allow more accurate results, samples should ideally be collected in a 
fasting state and the effect of drugs on the metabolome need to be carefully analyzed. Age, gender, 
body mass index and circadian rhythm should continue to be monitored. EBC remains an appealing 
matrix but potential biases, from environmental contamination to sample storage and processing, 
need to be carefully addressed. In particular, ambient air controls are mandatory and distinguishing 
exogenously originated metabolites in EBC, though challenging, is essential.  
Those metabolic pathways that are identified by metabolomics approaches require further analysis to 
confirm their potential role in disease states. One of the pathways that has been commonly identified 
by different research groups as a discriminating feature in asthma profiling in different matrixes is 
related to purine metabolism
(106, 114-117)
. Apart from molecular profiling studies, adenosine has been 
shown to be elevated in plasma, bronchoalveolar lavage fluid and EBC of asthmatic adults compared 
to healthy controls
(272-274)
. With regard to pediatric asthma, the only published study examining 
samples of EBC from 11 children showed that adenosine was significantly increased in asthmatic 
patients
(275)
. Adenosine is a well-known bronchoconstrictor stimulus that is also produced 
endogenously by many cells during hypoxia, allergic stimulation and exercise. The net effect of 
adenosine depends on the relative expression of adenosine receptors on different cell types, 
including epithelial smooth muscle cells, neurons and leukocytes. By acting on adenosine A1 
receptors, it produces bronchoconstriction and proinflammatory effects, while adenosine A2 and A3 
receptors activation induces the opposite
(276)
. Despite the evidence regarding the role of adenosine 
in asthma pathophysiology, to date no selective drug directed at this molecule has proved to be safe 
and effective, suggesting the possibility that similar structurally or functionally associated molecules 
may be potential new targets or are only effective in subgroups of patients
(276, 277)
. Deoxyadenosine, 
adenosine monophosphate and inosine have been identified as significantly altered in asthma 
metabolomics studies
(114, 115, 119)
. However, to date, there are no published studies that have made 
the joint analysis of these adenosine-like molecules in the airways of individuals with asthma. Our 
research team has made several efforts to develop and validate a high performance liquid-
chromatography method of increased sensitivity to quantify adenosine and related molecules and to 
evaluate its feasibility in EBC. Briefly, these have included derivatization coupled with fluorescence 
detection and a micro mass spectrometer equipped with an electrospray source and triple-
quadrupole analyzer. Methodologic developments performed by the Aveiro University research team 
are currently ongoing to optimize the minimum volume that is needed per EBC sample for this 
analysis, by improving extractive efficiency and selectivity, while avoiding molecules degradation, 
especially during the concentration steps. Using this method, we will be able to test the hypothesis 
that a panel of adenosine-related molecules quantification in EBC from patients with allergic rhinitis 
and asthma multimorbidity differs from healthy individuals.  
 
Asthma and rhinitis are complex diseases, where the combination of genetic information with 
environmental data is crucial. The combination of longitudinal raw data, especially coming from birth 
cohorts and moderate to severe patients’ cohorts, with flexible mathematical approaches is 
necessary to model the effects of time-invariant and time-variant factors and increase our 
understanding of asthma outcomes with multiple trajectories. These should help define different 
therapeutic strategies for each group or even for the individual patient, to be evaluated. The addition 
of biomarkers (single biomarkers, in panels or composite biomarkers) is critical to predict and 
evaluate outcomes and treatment responses. Novel treatments should be developed together with 
their biomarker for the selection of responsive patients. 
Multi-layered approaches that could integrate clinical data together with molecular data from 




an opportunity to investigate the system-wide changes in asthma and rhinitis and to complement 
existing knowledge into mechanistic understanding
(106, 107, 278)
. Large scale and integrative projects 
adopting a systems medicine approach in asthma and other respiratory and allergic diseases are 
ongoing, including AirPROM, EARIP, MeDALL and U-BIOPRED. Results and achievements of these 
consortia are becoming available
(28, 279-283)
, and currently leading to new disease classification 
hypotheses, aiming at improving the understanding of underlying pathophysiology mechanisms and 
better personalized disease management. The usefulness of these molecular asthma phenotypes 
has recently been demonstrated through transcriptomics-driven clustering approaches, namely 
identifying patients who may benefit from specific agents that target type 2-mediated inflammation 
and corticosteroid insensitivity
(284, 285)
. It may be necessary to use clustering methodologies that allow 
one element to belong to more than one cluster, instead of separate fixed individualized groups, as 
more than one pathophysiologic mechanism can occur simultaneously and involve common 
molecules. Relating molecules to their biological role will be the next step
(106, 107)
, in order to allow a 
mechanisms-based approach and targeted interventions. 
Big data mining may further assist to understand our current observations, in the progress from the 
broad asthma syndrome definition into individual “tailor-made” medicine, based in composite 
multiparametric profiles that may be unique to each person. This novel information can pave the way 
towards a new taxonomy of airway diseases
(16)
. 
Integration of artificial intelligence in clinical care will benefit building of predictive models to support 
decision-making and further advance into precision medicine aimed at better quality of life with more 
efficient, preventive strategies at the individual level. These strategies can benefit from technological 
and therapeutic innovations, but also from resetting current existing treatments that may have been 
potentially hampered by the general assumptions of current “asthma label” definition
(17)
.  
Besides the aforementioned unmet needs, others remain essential current problems in asthma and 
rhinitis. So far, given the chronic nature of the diseases, major issues relate to patient adherence to 
treatment and self-management
(6, 22, 286)
. Once again, approaches that consider individual needs are 
most likely to be successful. In particular, severe asthma continues to represent one of the most 
significant burdens of the disease from all perspectives of affected patients and health care system, 
where the definition of endotypes is urgently required for personalized treatment
(287, 288)
. Asthma 
exacerbations constitute the biggest immediate risk and anxiety to patients and their families, linked 
to lung function decline and huge financial burden in health care systems
(2)
. Preventive strategies 
need to be improved to avoid the effect of common triggers and other risk factors. 
In summary, coupling individual unmet needs with evidence-based medicine developments will be 
critical for the succeeding advances in the history of rhinitis and asthma multimorbidity. Increased 
knowledge on pathophysiologic mechanisms opens the possibility of new efficient treatments that 
aim not only at the temporary relief of symptoms but to long-term disease-modifying effects. It should 
also contribute to global prevention strategies, answering relevant current questions at the individual 
level, namely: “Will my child develop asthma/rhinitis?”, “Is there a way to prevent these diseases 
development?”, “If they develop, will it be possible to outgrow asthma/rhinitis and associated 
diseases?” 
 
The way forward is to continue to pursue the aim of understanding the beauty of health and the 
mechanisms involved in rhinitis and asthma multimorbidity, ultimately enabling to propose relevant 
therapeutic strategies for each individual person, while using our best current evidence-based 
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